Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2866097,spectral dissociation constant (Ks),"Cimetidine induced binding changes with a spectral dissociation constant (Ks) of 0.87 mM, whereas famotidine produced no measurable spectral alteration in concentrations up to 4 mM.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),mM,0.87,1804,DB01035,Procainamide
,2866097,elimination half-life (t1/2,The elimination half-life (t1/2: 45.6 h) and total plasma clearance (CL: 0.28 ml/min/kg) of diazepam were not significantly altered by famotidine (t1/2 = 39.0 +/- 11.4 h; CL = 0.31 +/- 0.08 ml/min/kg).,"Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),h,45.6,1805,DB01035,Procainamide
,2866097,total plasma clearance (CL,The elimination half-life (t1/2: 45.6 h) and total plasma clearance (CL: 0.28 ml/min/kg) of diazepam were not significantly altered by famotidine (t1/2 = 39.0 +/- 11.4 h; CL = 0.31 +/- 0.08 ml/min/kg).,"Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [kg·min],0.28,1806,DB01035,Procainamide
,2866097,t1/2,The elimination half-life (t1/2: 45.6 h) and total plasma clearance (CL: 0.28 ml/min/kg) of diazepam were not significantly altered by famotidine (t1/2 = 39.0 +/- 11.4 h; CL = 0.31 +/- 0.08 ml/min/kg).,"Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),h,39.0,1807,DB01035,Procainamide
,2866097,CL,The elimination half-life (t1/2: 45.6 h) and total plasma clearance (CL: 0.28 ml/min/kg) of diazepam were not significantly altered by famotidine (t1/2 = 39.0 +/- 11.4 h; CL = 0.31 +/- 0.08 ml/min/kg).,"Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [kg·min],0.31,1808,DB01035,Procainamide
,2866097,t1/2,"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),h,2.9,1809,DB01035,Procainamide
,2866097,t1/2,"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),h,3.0,1810,DB01035,Procainamide
,2866097,renal clearance (CLR),"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [min],436,1811,DB01035,Procainamide
,2866097,renal clearance (CLR),"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [min],443,1812,DB01035,Procainamide
,2866097,CLR,"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [min],195,1813,DB01035,Procainamide
,2866097,CLR,"The pharmacodynamics and pharmacokinetics of procainamide and N-acetylprocainamide (NAPA), too, were not significantly changed by famotidine: procainamide t1/2 2.9 vs 3.0 h under famotidine and renal clearance (CLR) 436 vs 443 ml/min; and NAPA CLR 195 vs 212 ml/min under famotidine.","Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866097/),[ml] / [min],212,1814,DB01035,Procainamide
,497093,half-life,Both effectively double the half-life of conventional oral procainamide to 6.5 h and are suitable as prophylactic preparations.,A pharmacokinetic comparison of two sustained-release oral procainamide preparations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/497093/),h,6.5,3157,DB01035,Procainamide
,2431636,elimination half-life,"The elimination half-life was 2.43 hours, the apparent volume of distribution was 1.44 L/kg, and the systemic clearance was 0.412 L/kg/hr.",Pharmacokinetics of procainamide hydrochloride in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2431636/),h,2.43,4565,DB01035,Procainamide
,2431636,apparent volume of distribution,"The elimination half-life was 2.43 hours, the apparent volume of distribution was 1.44 L/kg, and the systemic clearance was 0.412 L/kg/hr.",Pharmacokinetics of procainamide hydrochloride in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2431636/),[l] / [kg],1.44,4566,DB01035,Procainamide
,2431636,systemic clearance,"The elimination half-life was 2.43 hours, the apparent volume of distribution was 1.44 L/kg, and the systemic clearance was 0.412 L/kg/hr.",Pharmacokinetics of procainamide hydrochloride in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2431636/),[l] / [h·kg],0.412,4567,DB01035,Procainamide
,2431636,elimination half-life,"The elimination half-life for the IV dosage was 2.85 hours, the apparent volume of distribution was 2.13 L/kg, and the systemic clearance was 0.519 L/kg/hr.",Pharmacokinetics of procainamide hydrochloride in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2431636/),h,2.85,4568,DB01035,Procainamide
,2431636,apparent volume of distribution,"The elimination half-life for the IV dosage was 2.85 hours, the apparent volume of distribution was 2.13 L/kg, and the systemic clearance was 0.519 L/kg/hr.",Pharmacokinetics of procainamide hydrochloride in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2431636/),[l] / [kg],2.13,4569,DB01035,Procainamide
,2431636,systemic clearance,"The elimination half-life for the IV dosage was 2.85 hours, the apparent volume of distribution was 2.13 L/kg, and the systemic clearance was 0.519 L/kg/hr.",Pharmacokinetics of procainamide hydrochloride in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2431636/),[l] / [h·kg],0.519,4570,DB01035,Procainamide
,2431636,bioavailability,"For the orally administered dose, the bioavailability was 85%, and the absorption half-life was 0.5 hours.",Pharmacokinetics of procainamide hydrochloride in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2431636/),%,85,4571,DB01035,Procainamide
,2431636,absorption half-life,"For the orally administered dose, the bioavailability was 85%, and the absorption half-life was 0.5 hours.",Pharmacokinetics of procainamide hydrochloride in dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2431636/),h,0.5,4572,DB01035,Procainamide
,2431636,elimination half-life,The estimated elimination half-life of NAPA was 4.7 hours.,Pharmacokinetics of procainamide hydrochloride in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2431636/),h,4.7,4573,DB01035,Procainamide
,6167709,biological half-lives,"The biological half-lives of procainamide and N-acetylprocainamide averaged 0.66 and 2.1 hr, respectively.",Pharmacokinetics of procainamide and N-acetylprocainamide in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6167709/),h,0.66,7332,DB01035,Procainamide
,6167709,biological half-lives,"The biological half-lives of procainamide and N-acetylprocainamide averaged 0.66 and 2.1 hr, respectively.",Pharmacokinetics of procainamide and N-acetylprocainamide in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6167709/),h,2.1,7333,DB01035,Procainamide
,1702691,intestinal,"The intestinal and peritoneal clearance values of procainamide were 143.5 and 59.4 ml/h, respectively, and those of NAPA were 32.6 and 13.5 ml/h.",Comparison of transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen with that into the peritoneal cavity in rats. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1702691/),[ml] / [h],143.5,9568,DB01035,Procainamide
,1702691,intestinal,"The intestinal and peritoneal clearance values of procainamide were 143.5 and 59.4 ml/h, respectively, and those of NAPA were 32.6 and 13.5 ml/h.",Comparison of transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen with that into the peritoneal cavity in rats. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1702691/),[ml] / [h],32.6,9569,DB01035,Procainamide
,1702691,peritoneal clearance,"The intestinal and peritoneal clearance values of procainamide were 143.5 and 59.4 ml/h, respectively, and those of NAPA were 32.6 and 13.5 ml/h.",Comparison of transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen with that into the peritoneal cavity in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1702691/),[ml] / [h],59.4,9570,DB01035,Procainamide
,1702691,peritoneal clearance,"The intestinal and peritoneal clearance values of procainamide were 143.5 and 59.4 ml/h, respectively, and those of NAPA were 32.6 and 13.5 ml/h.",Comparison of transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen with that into the peritoneal cavity in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1702691/),[ml] / [h],32.6,9571,DB01035,Procainamide
,1702691,peritoneal clearance,"The intestinal and peritoneal clearance values of procainamide were 143.5 and 59.4 ml/h, respectively, and those of NAPA were 32.6 and 13.5 ml/h.",Comparison of transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen with that into the peritoneal cavity in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1702691/),[ml] / [h],13.5,9572,DB01035,Procainamide
,1726674,clearances,"The estimated clearances of PA in rat blood, kidney and liver were 47. 28, 13. 56 and and 33. 71 ml.kg-1.min-1, respectively.",[Simultaneous predictions of disposition kinetics of procainamide and its metabolite N-acetylprocainamide in rat by a physiological pharmacokinetic model]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726674/),[ml] / [kg·min],47. 28,12478,DB01035,Procainamide
,1726674,clearances,"The estimated clearances of PA in rat blood, kidney and liver were 47. 28, 13. 56 and and 33. 71 ml.kg-1.min-1, respectively.",[Simultaneous predictions of disposition kinetics of procainamide and its metabolite N-acetylprocainamide in rat by a physiological pharmacokinetic model]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726674/),[ml] / [kg·min],13. 56,12479,DB01035,Procainamide
,1726674,clearances,"The estimated clearances of PA in rat blood, kidney and liver were 47. 28, 13. 56 and and 33. 71 ml.kg-1.min-1, respectively.",[Simultaneous predictions of disposition kinetics of procainamide and its metabolite N-acetylprocainamide in rat by a physiological pharmacokinetic model]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726674/),[ml] / [kg·min],33. 71,12480,DB01035,Procainamide
,2439251,volume of distribution,"NAPA volume of distribution, elimination clearance, and elimination half-life averaged 1.37 +/- 0.19 L/kg, 174 +/- 63 ml/min, and 8.2 +/- 1.4 hours, respectively (mean +/- SD), and NAPA renal clearance averaged 1.9 +/- 0.6 times creatinine clearance.",Effect kinetics of N-acetylprocainamide-induced QT interval prolongation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439251/),[l] / [kg],1.37,13271,DB01035,Procainamide
,2439251,elimination clearance,"NAPA volume of distribution, elimination clearance, and elimination half-life averaged 1.37 +/- 0.19 L/kg, 174 +/- 63 ml/min, and 8.2 +/- 1.4 hours, respectively (mean +/- SD), and NAPA renal clearance averaged 1.9 +/- 0.6 times creatinine clearance.",Effect kinetics of N-acetylprocainamide-induced QT interval prolongation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439251/),[ml] / [min],174,13272,DB01035,Procainamide
,2439251,elimination half-life,"NAPA volume of distribution, elimination clearance, and elimination half-life averaged 1.37 +/- 0.19 L/kg, 174 +/- 63 ml/min, and 8.2 +/- 1.4 hours, respectively (mean +/- SD), and NAPA renal clearance averaged 1.9 +/- 0.6 times creatinine clearance.",Effect kinetics of N-acetylprocainamide-induced QT interval prolongation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439251/),h,8.2,13273,DB01035,Procainamide
,7175718,overall clearance,Pharmacokinetic analysis via the two-compartment open model showed that bile duct ligation caused a decrease in overall clearance from approximately 61.94 to 28.71 ml/kg/min.,Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175718/),[ml] / [kg·min],61.94,15479,DB01035,Procainamide
,7175718,overall clearance,Pharmacokinetic analysis via the two-compartment open model showed that bile duct ligation caused a decrease in overall clearance from approximately 61.94 to 28.71 ml/kg/min.,Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175718/),[ml] / [kg·min],28.71,15480,DB01035,Procainamide
,7175718,apparent volume of distribution,The significant reduction in the apparent volume of distribution from 3.76 to 2.72 liter/kg could be the result of reduced binding sites.,Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175718/),[l] / [kg],3.76,15481,DB01035,Procainamide
,7175718,apparent volume of distribution,The significant reduction in the apparent volume of distribution from 3.76 to 2.72 liter/kg could be the result of reduced binding sites.,Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175718/),[l] / [kg],2.72,15482,DB01035,Procainamide
,7175718,elimination half-life,There was also a significant increase in the elimination half-life of procainamide from 47.39 to 78.64 min in bile duct ligated rats.,Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175718/),min,47.39,15483,DB01035,Procainamide
,7175718,elimination half-life,There was also a significant increase in the elimination half-life of procainamide from 47.39 to 78.64 min in bile duct ligated rats.,Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175718/),min,78.64,15484,DB01035,Procainamide
,6161534,plasma concentration,"The mean plasma concentration associated with 90 percent suppression of arrhythmia in these two patients ws 12.6 and 32.3 mg/ml, respectively.",Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6161534/),[mg] / [ml],12.6,21048,DB01035,Procainamide
,6161534,plasma concentration,"The mean plasma concentration associated with 90 percent suppression of arrhythmia in these two patients ws 12.6 and 32.3 mg/ml, respectively.",Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6161534/),[mg] / [ml],32.3,21049,DB01035,Procainamide
,6161534,half-life,"NAPA obeyed linear pharmacokinetics over the range of dosages studied (500 to 2,500 mg every 8 hours) and had a half-life of 10.7 +/- 1.98 hours (mean +/- standard deviation).",Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6161534/),h,10.7,21050,DB01035,Procainamide
,3292102,body clearance,"In healthy subjects given captopril intravenously, the body clearance of captopril and steady-state volume of distribution were about 0.7 L/h/kg and 0.8 L/kg, respectively.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),[l] / [h·kg],0.7,28702,DB01035,Procainamide
,3292102,steady-state volume of distribution,"In healthy subjects given captopril intravenously, the body clearance of captopril and steady-state volume of distribution were about 0.7 L/h/kg and 0.8 L/kg, respectively.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),[l] / [kg],0.8,28703,DB01035,Procainamide
,3292102,elimination half-life,The elimination half-life of unchanged captopril was approximately 2 hours.,Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),h,2,28704,DB01035,Procainamide
,3292102,bioavailability,"In healthy subjects, about 70 to 75% of an oral dose is absorbed and the bioavailability of captopril is approximately 65%.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),%,65,28705,DB01035,Procainamide
,3243920,peak plasma concentration,The average peak plasma concentration was 15.8 +/- 9.6 micrograms/ml and the average maximum QRS interval prolongation was 23.9 +/- 6.8% from baseline.,Pharmacodynamics of procainamide in patients with ventricular tachyarrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243920/),[μg] / [ml],15.8,30917,DB01035,Procainamide
,3806778,plasma concentration,All six dogs that received procainamide converted to a normal sinus cardiac rhythm after attaining a mean plasma concentration of 33.8 micrograms/ml with a range of 48.5 micrograms/ml-25.0 micrograms/ml.,Procainamide in the dog: antiarrhythmic plasma concentrations after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806778/),[μg] / [ml],33.8,33548,DB01035,Procainamide
∼,21677062,IC(50),"However, it did inhibit the RLS9-catalyzed N-acetylation of procainamide (IC(50) ∼ 30 μM), and no preincubation time dependence was evident.","1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21677062/),μM,30,33629,DB01035,Procainamide
,21677062,IC(50),Additional studies with human forms of NAT (hNAT1 and hNAT2) revealed that ABT is a more potent inhibitor of hNAT2 compared with hNAT1 (IC(50) 158 μM versus > 1 mM).,"1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21677062/),μM,158,33630,DB01035,Procainamide
>,21677062,IC(50),Additional studies with human forms of NAT (hNAT1 and hNAT2) revealed that ABT is a more potent inhibitor of hNAT2 compared with hNAT1 (IC(50) 158 μM versus > 1 mM).,"1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21677062/),mM,1,33631,DB01035,Procainamide
,21677062,inhibition constant,"Consistent with the IC(50) estimate, formal inhibition studies revealed that inhibition of hNAT2 was competitive with an inhibition constant of 67 μM.","1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21677062/),μM,67,33632,DB01035,Procainamide
,346289,plasma half-life during the beta-phase,The plasma half-life during the beta-phase averages 3 hours.,Clinical pharmacokinetics of procainamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/346289/),h,3,36593,DB01035,Procainamide
,346289,apparent volume of distribution,The apparent volume of distribution is about 2L/kg body weight.,Clinical pharmacokinetics of procainamide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346289/),[l] / [kg],2,36594,DB01035,Procainamide
,346289,recovery,"N-Acetylprocainamide is the main metabolite and is the main metabolite and is pharmacologically active, with a recovery in urine of about 15% (range 7 to 34% in healthy subjects).",Clinical pharmacokinetics of procainamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346289/),%,15,36595,DB01035,Procainamide
,346289,renal clearance,The renal clearance of procainamide ranges from 179 to 660ml/min.,Clinical pharmacokinetics of procainamide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346289/),[ml] / [min],179 to 660,36596,DB01035,Procainamide
,3061720,systemic bioavailability,"It is well absorbed after oral administration, but systemic bioavailability is only 12% after a 300-mg dose.",Propafenone: a new antiarrhythmic agent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),%,12,37633,DB01035,Procainamide
,3061720,elimination half-life,"Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers.",Propafenone: a new antiarrhythmic agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),h,5.5,37634,DB01035,Procainamide
,3061720,elimination half-life,"Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers.",Propafenone: a new antiarrhythmic agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),h,17.2,37635,DB01035,Procainamide
,3348317,coefficient of elimination,"After direct fetal digitalization we calculated that the coefficient of elimination for digoxin from the fetus was 0.0463 h-1, and digoxin elimination half-life was 15.9 hours.",Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348317/),1/[h],0.0463,47668,DB01035,Procainamide
,3348317,elimination half-life,"After direct fetal digitalization we calculated that the coefficient of elimination for digoxin from the fetus was 0.0463 h-1, and digoxin elimination half-life was 15.9 hours.",Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348317/),h,15.9,47669,DB01035,Procainamide
,3348317,half,The latter time span is substantially less than the 50-hour half-life previously reported in newborn infants with low birth weight.,Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348317/),h,50,47670,DB01035,Procainamide
,3348317,f,The fetal/maternal concentration ratio of procainamide was 0.914.,Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348317/),,0.91,47671,DB01035,Procainamide
,3348317,concentration ratio,The fetal/maternal concentration ratio of procainamide was 0.914.,Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348317/),,0.91,47672,DB01035,Procainamide
,3348317,clearance,"However, maternal clearance of procainamide (9.7 ml/kg-1/min-1) was twice as long as the clearance reported for nonpregnant patients undergoing fast acetylation.",Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348317/),[ml] / [kg],9.7,47673,DB01035,Procainamide
,6160014,clearance of NAPA (ClD),"The deacetylation clearance of NAPA (ClD) was found to be 6.5 ml/min whereas total NAPA elimination clearance was 231 ml/min, so that 2.8% of the administered NAPA-13C was metabolized by deacetylation.",Kinetics of N-acetylprocainamide deacetylation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160014/),[ml] / [min],6.5,51501,DB01035,Procainamide
,6160014,elimination clearance,"The deacetylation clearance of NAPA (ClD) was found to be 6.5 ml/min whereas total NAPA elimination clearance was 231 ml/min, so that 2.8% of the administered NAPA-13C was metabolized by deacetylation.",Kinetics of N-acetylprocainamide deacetylation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160014/),[ml] / [min],231,51502,DB01035,Procainamide
,6160014,Steady-state,"Steady-state [PA]/[NAPA] ratios averaged 0.024, but would be expected to rise to 0.057 if functionally anephric patients were treated with NAPA.",Kinetics of N-acetylprocainamide deacetylation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160014/),,0.024,51503,DB01035,Procainamide
,6160014,Steady-state,"Steady-state [PA]/[NAPA] ratios averaged 0.024, but would be expected to rise to 0.057 if functionally anephric patients were treated with NAPA.",Kinetics of N-acetylprocainamide deacetylation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160014/),,0.057,51504,DB01035,Procainamide
,6194997,area under the procainamide plasma concentration-time curve,The area under the procainamide plasma concentration-time curve was increased by cimetidine by an average of 35% from 27.0 +/- 0.3 micrograms/ml X h to 36.5 +/- 3.4 micrograms/ml X h.,Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6194997/),[μg] / [h·ml],27.0,53667,DB01035,Procainamide
,6194997,area under the procainamide plasma concentration-time curve,The area under the procainamide plasma concentration-time curve was increased by cimetidine by an average of 35% from 27.0 +/- 0.3 micrograms/ml X h to 36.5 +/- 3.4 micrograms/ml X h.,Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6194997/),[μg] / [h·ml],36.5,53668,DB01035,Procainamide
,6194997,elimination half-life,The elimination half-life increased from an harmonic mean of 2.92 to 3.68 h.,Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6194997/),h,2.92,53669,DB01035,Procainamide
,6194997,elimination half-life,The elimination half-life increased from an harmonic mean of 2.92 to 3.68 h.,Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6194997/),h,3.68,53670,DB01035,Procainamide
,6194997,renal clearance,The renal clearance of procainamide was reduced by cimetidine from 347 +/- 46 ml/min to 196 +/- 11 ml/min.,Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6194997/),[ml] / [min],347,53671,DB01035,Procainamide
,6194997,renal clearance,The renal clearance of procainamide was reduced by cimetidine from 347 +/- 46 ml/min to 196 +/- 11 ml/min.,Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6194997/),[ml] / [min],196,53672,DB01035,Procainamide
,6194997,renal clearance,The area under the plasma concentration-time curve for n-acetylprocainamide was increased by a mean of 25% by cimetidine due to a significant (p less than 0.016) reduction in renal clearance from 258 +/- 60 ml/min to 197 +/- 59 ml/min.,Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6194997/),[ml] / [min],258,53673,DB01035,Procainamide
,6194997,renal clearance,The area under the plasma concentration-time curve for n-acetylprocainamide was increased by a mean of 25% by cimetidine due to a significant (p less than 0.016) reduction in renal clearance from 258 +/- 60 ml/min to 197 +/- 59 ml/min.,Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6194997/),[ml] / [min],197,53674,DB01035,Procainamide
,2453956,biological half-life,The reported biological half-life of the antiarrhythmic drug procainamide (PA) is between 2 and 4 h.,Longer plasma half-life for procainamide utilizing a very sensitive high performance liquid chromatography assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453956/),h,2 and 4,56576,DB01035,Procainamide
,2453956,minimum quantifiable concentration,The minimum quantifiable concentration was 0.005 microgram/ml for both the drug and its metabolite.,Longer plasma half-life for procainamide utilizing a very sensitive high performance liquid chromatography assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453956/),[μg] / [ml],0.005,56577,DB01035,Procainamide
,2453956,t1/2,"When only the data points up to 12 h were included in the calculation, the drug t1/2 was 3.50 +/- 0.82 h (mean +/- SD) and in agreement with those reported previously.",Longer plasma half-life for procainamide utilizing a very sensitive high performance liquid chromatography assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453956/),h,3.50,56578,DB01035,Procainamide
,2453956,t1/2,"However, the t1/2 became significantly longer (8.52 +/- 3.58 h) when the 16- and 24-h data points were also included.",Longer plasma half-life for procainamide utilizing a very sensitive high performance liquid chromatography assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453956/),h,8.52,56579,DB01035,Procainamide
,2453956,t1/2,The t1/2 of NAPA was 8.06 +/- 1.33 h and close to the reported values.,Longer plasma half-life for procainamide utilizing a very sensitive high performance liquid chromatography assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453956/),h,8.06,56580,DB01035,Procainamide
,2882974,Basal bile flow rates,Basal bile flow rates were increased by 62% after the induction of diabetes to 88 microliter/min/kg.,Alterations in biliary excretory function by streptozotocin-induced diabetes. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882974/),[μl] / [kg·min],88,56721,DB01035,Procainamide
,8585104,renal clearances,The respective renal clearances were 250 (41) ml.min-1 and 222 (44) ml.min-1.,Kinetics and dynamics of sematilide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585104/),[ml] / [min],250,57001,DB01035,Procainamide
,8585104,renal clearances,The respective renal clearances were 250 (41) ml.min-1 and 222 (44) ml.min-1.,Kinetics and dynamics of sematilide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585104/),[ml] / [min],222,57002,DB01035,Procainamide
,8585104,bioavailability,The bioavailability of sematilide was 0.47 (0.15).,Kinetics and dynamics of sematilide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585104/),,0.47,57003,DB01035,Procainamide
,8585104,maximum percent effect,A maximum percent effect on QTc of 12 (1)% occurred with a delay of 14 min after termination of an intravenous infusion of 10 min.,Kinetics and dynamics of sematilide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585104/),%,12,57004,DB01035,Procainamide
,2471472,renal clearance,Trimethoprim decreased the mean (+/- SD) renal clearance by 45% after the dose of procainamide was administered (487 +/- 129 vs 267 +/- 123 mL/min) and that of N-acetylprocainamide by 26% (275 +/- 78 vs 192 +/- 82 mL/min) compared with placebo.,Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471472/),[ml] / [min],487,57181,DB01035,Procainamide
,2471472,renal clearance,Trimethoprim decreased the mean (+/- SD) renal clearance by 45% after the dose of procainamide was administered (487 +/- 129 vs 267 +/- 123 mL/min) and that of N-acetylprocainamide by 26% (275 +/- 78 vs 192 +/- 82 mL/min) compared with placebo.,Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471472/),[ml] / [min],267,57182,DB01035,Procainamide
,2471472,renal clearance,Trimethoprim decreased the mean (+/- SD) renal clearance by 45% after the dose of procainamide was administered (487 +/- 129 vs 267 +/- 123 mL/min) and that of N-acetylprocainamide by 26% (275 +/- 78 vs 192 +/- 82 mL/min) compared with placebo.,Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471472/),[ml] / [min],275,57183,DB01035,Procainamide
,2471472,renal clearance,Trimethoprim decreased the mean (+/- SD) renal clearance by 45% after the dose of procainamide was administered (487 +/- 129 vs 267 +/- 123 mL/min) and that of N-acetylprocainamide by 26% (275 +/- 78 vs 192 +/- 82 mL/min) compared with placebo.,Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471472/),[ml] / [min],192,57184,DB01035,Procainamide
,2471472,area under plasma concentration--time curve 0 to 12 hours,The mean area under plasma concentration--time curve 0 to 12 hours after dosing increased 39% for procainamide (19.8 +/- 4.8 vs 27.6 +/- 7.2 mg.h/L) and 27% for N-acetylprocainamide (9.1 +/- 2.1 vs 11.4 +/- 2.8 mg.h/L).,Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471472/),[h·mg] / [l],19.8,57185,DB01035,Procainamide
,2471472,area under plasma concentration--time curve 0 to 12 hours,The mean area under plasma concentration--time curve 0 to 12 hours after dosing increased 39% for procainamide (19.8 +/- 4.8 vs 27.6 +/- 7.2 mg.h/L) and 27% for N-acetylprocainamide (9.1 +/- 2.1 vs 11.4 +/- 2.8 mg.h/L).,Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471472/),[h·mg] / [l],27.6,57186,DB01035,Procainamide
,2471472,area under plasma concentration--time curve 0 to 12 hours,The mean area under plasma concentration--time curve 0 to 12 hours after dosing increased 39% for procainamide (19.8 +/- 4.8 vs 27.6 +/- 7.2 mg.h/L) and 27% for N-acetylprocainamide (9.1 +/- 2.1 vs 11.4 +/- 2.8 mg.h/L).,Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471472/),[h·mg] / [l],9.1,57187,DB01035,Procainamide
,2471472,area under plasma concentration--time curve 0 to 12 hours,The mean area under plasma concentration--time curve 0 to 12 hours after dosing increased 39% for procainamide (19.8 +/- 4.8 vs 27.6 +/- 7.2 mg.h/L) and 27% for N-acetylprocainamide (9.1 +/- 2.1 vs 11.4 +/- 2.8 mg.h/L).,Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471472/),[h·mg] / [l],11.4,57188,DB01035,Procainamide
,2474402,central compartment volume,"The central compartment volume of 14.1 +/- 2.6 L (mean +/- SD) was similar to expected intravascular space, corrected for NAPA partitioning between erythrocytes and plasma.",Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2474402/),l,14.1,61666,DB01035,Procainamide
,2474402,steady-state distribution volume,"Other compartment volumes, intercompartmental and nonrenal clearances, and the steady-state distribution volume of 1.45 +/- 0.09 L/kg were similar to normal subject values.",Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2474402/),[l] / [kg],1.45,61667,DB01035,Procainamide
,902457,steady-state distribution volumes,"The distribution kinetics of both compounds were modeled with a 3-compartment mamillary system, and it was found that their steady-state distribution volumes were not significantly different, averaging 1.41 L/kg for PA and 1.46 L/kg for NAPA.",Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902457/),[l] / [kg],1.41,62910,DB01035,Procainamide
,902457,steady-state distribution volumes,"The distribution kinetics of both compounds were modeled with a 3-compartment mamillary system, and it was found that their steady-state distribution volumes were not significantly different, averaging 1.41 L/kg for PA and 1.46 L/kg for NAPA.",Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902457/),[l] / [kg],1.46,62911,DB01035,Procainamide
,902457,elimination t1/2,"In these normal subjects, the average elimination t1/2 and total elimination clearance for PA were 2.5 hr and 589.8 ml/min, and for NAPA were 6.2 hr and 233.7 ml/min.",Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/902457/),h,2.5,62912,DB01035,Procainamide
,902457,elimination t1/2,"In these normal subjects, the average elimination t1/2 and total elimination clearance for PA were 2.5 hr and 589.8 ml/min, and for NAPA were 6.2 hr and 233.7 ml/min.",Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/902457/),h,6.2,62913,DB01035,Procainamide
,902457,total elimination clearance,"In these normal subjects, the average elimination t1/2 and total elimination clearance for PA were 2.5 hr and 589.8 ml/min, and for NAPA were 6.2 hr and 233.7 ml/min.",Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902457/),[ml] / [min],589.8,62914,DB01035,Procainamide
,902457,total elimination clearance,"In these normal subjects, the average elimination t1/2 and total elimination clearance for PA were 2.5 hr and 589.8 ml/min, and for NAPA were 6.2 hr and 233.7 ml/min.",Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902457/),[ml] / [min],233.7,62915,DB01035,Procainamide
,902457,renal clearances,"Mean renal clearances of PA (346.7 ml/min) and of NAPA (199.5 ml/min) exceeded the usual rate of glomerular filtration, which suggests that both compounds are eliminated in part by renal tubular secretion.",Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902457/),[ml] / [min],346.7,62916,DB01035,Procainamide
,902457,renal clearances,"Mean renal clearances of PA (346.7 ml/min) and of NAPA (199.5 ml/min) exceeded the usual rate of glomerular filtration, which suggests that both compounds are eliminated in part by renal tubular secretion.",Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902457/),[ml] / [min],199.5,62917,DB01035,Procainamide
,12820417,% ISCL,The analysis of binding of Pt to DNA and percent interstrand cross-links (%ISCL) in P388 tumour cells showed that the % ISCL (10.44 +/- 3.81% vs. 3.51 +/- 0.01%) and the efficiency of ISCL formation (0.51 +/- 0.14 vs. 0.17 +/- 0.02 %ISCL.microgram DNA/pg Pt) were significantly greater when cisplatin was administered in association with procainamide hydrochloride.,Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820417/),%,10.44,65081,DB01035,Procainamide
,12820417,% ISCL,The analysis of binding of Pt to DNA and percent interstrand cross-links (%ISCL) in P388 tumour cells showed that the % ISCL (10.44 +/- 3.81% vs. 3.51 +/- 0.01%) and the efficiency of ISCL formation (0.51 +/- 0.14 vs. 0.17 +/- 0.02 %ISCL.microgram DNA/pg Pt) were significantly greater when cisplatin was administered in association with procainamide hydrochloride.,Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820417/),%,3.51,65082,DB01035,Procainamide
,1153866,half-life,"The values of half-life (2.08 +/- 0.52 hr), volume of distribution (4.3 +/- 0.6 1/Kg) and total body clearance (1344 +/- 238 ml/min) found in this study differed from those previously reported.",The pharmacokinetics of procainamide in normal subjects using a specific gas chromatographic assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1153866/),h,2.08,71033,DB01035,Procainamide
,1153866,volume of distribution,"The values of half-life (2.08 +/- 0.52 hr), volume of distribution (4.3 +/- 0.6 1/Kg) and total body clearance (1344 +/- 238 ml/min) found in this study differed from those previously reported.",The pharmacokinetics of procainamide in normal subjects using a specific gas chromatographic assay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1153866/),[1] / [kg],4.3,71034,DB01035,Procainamide
,1153866,total body clearance,"The values of half-life (2.08 +/- 0.52 hr), volume of distribution (4.3 +/- 0.6 1/Kg) and total body clearance (1344 +/- 238 ml/min) found in this study differed from those previously reported.",The pharmacokinetics of procainamide in normal subjects using a specific gas chromatographic assay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1153866/),[ml] / [min],1344,71035,DB01035,Procainamide
,2476614,pseudo-equilibrium plasma concentration,"On study days 2 and 3, NAPA was administered as a loading and maintenance infusion designed to reach a target pseudo-equilibrium plasma concentration of 8 micrograms/ml.",Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2476614/),[μg] / [ml],8,77600,DB01035,Procainamide
,2476614,elimination half-life (t1/2),NAPA increased procainamide elimination half-life (t1/2) from 275 +/- 42 min (mean +/- SD) on day 1 to 340 +/- 74 min on day 2 (p less than 0.01).,Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2476614/),min,275,77601,DB01035,Procainamide
,2476614,elimination half-life (t1/2),NAPA increased procainamide elimination half-life (t1/2) from 275 +/- 42 min (mean +/- SD) on day 1 to 340 +/- 74 min on day 2 (p less than 0.01).,Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2476614/),min,340,77602,DB01035,Procainamide
,29601501,flow rate,"A simple deproteinization method with methanol was applied to the rat plasma samples, which were analyzed using UHPLC equipped with DAD at 280 nm, and a Synergi™ 4 µm polar, reversed-phase column using 1% acetic acid (pH 5.5) and methanol (76:24, v/v) as eluent in isocratic mode at a flow rate 0.2 mL/min.",Simultaneous Determination of Procainamide and N-acetylprocainamide in Rat Plasma by Ultra-High-Pressure Liquid Chromatography Coupled with a Diode Array Detector and Its Application to a Pharmacokinetic Study in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29601501/),[ml] / [min],0.2,78844,DB01035,Procainamide
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],378,80807,DB01035,Procainamide
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],309,80808,DB01035,Procainamide
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],66.7,80809,DB01035,Procainamide
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],48,80810,DB01035,Procainamide
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],42.9,80811,DB01035,Procainamide
,6196373,detection limits,"Using 100-microliter samples, detection limits were 60 ng of procainamide-HCl per ml serum and 7 micrograms/ml urine, and 60 ng of N-acetylprocainamide-HCl per ml serum and 5 micrograms/ml urine.",Thin-layer chromatographic determination of procainamide and N-acetylprocainamide in human serum and urine at single-dose levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6196373/),ng,60,84839,DB01035,Procainamide
,975731,apparent volume,"The apparent volume of procainamide distribution was reduced from a normal value of 2 L/kg to 0.76 L/kg, and that of NAPA from 1.4 L/kg to 0.63 L/kg.",Hemodialysis for severe procainamide toxicity: clinical and pharmacokinetic observations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/975731/),[l] / [kg],2,87135,DB01035,Procainamide
,975731,apparent volume,"The apparent volume of procainamide distribution was reduced from a normal value of 2 L/kg to 0.76 L/kg, and that of NAPA from 1.4 L/kg to 0.63 L/kg.",Hemodialysis for severe procainamide toxicity: clinical and pharmacokinetic observations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/975731/),[l] / [kg],0.76,87136,DB01035,Procainamide
,975731,apparent volume,"The apparent volume of procainamide distribution was reduced from a normal value of 2 L/kg to 0.76 L/kg, and that of NAPA from 1.4 L/kg to 0.63 L/kg.",Hemodialysis for severe procainamide toxicity: clinical and pharmacokinetic observations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/975731/),[l] / [kg],1.4,87137,DB01035,Procainamide
,975731,apparent volume,"The apparent volume of procainamide distribution was reduced from a normal value of 2 L/kg to 0.76 L/kg, and that of NAPA from 1.4 L/kg to 0.63 L/kg.",Hemodialysis for severe procainamide toxicity: clinical and pharmacokinetic observations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/975731/),[l] / [kg],0.63,87138,DB01035,Procainamide
,975731,elimination + 1/2,"The elimination + 1/2 of procainamide was prolonged from the normal of 3 hr to 10.5 hr, and that of NAPA from 6 to 35.9 hr.",Hemodialysis for severe procainamide toxicity: clinical and pharmacokinetic observations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/975731/),h,3,87139,DB01035,Procainamide
,975731,elimination + 1/2,"The elimination + 1/2 of procainamide was prolonged from the normal of 3 hr to 10.5 hr, and that of NAPA from 6 to 35.9 hr.",Hemodialysis for severe procainamide toxicity: clinical and pharmacokinetic observations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/975731/),h,10.5,87140,DB01035,Procainamide
,975731,elimination + 1/2,"The elimination + 1/2 of procainamide was prolonged from the normal of 3 hr to 10.5 hr, and that of NAPA from 6 to 35.9 hr.",Hemodialysis for severe procainamide toxicity: clinical and pharmacokinetic observations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/975731/),h,6,87141,DB01035,Procainamide
,975731,elimination + 1/2,"The elimination + 1/2 of procainamide was prolonged from the normal of 3 hr to 10.5 hr, and that of NAPA from 6 to 35.9 hr.",Hemodialysis for severe procainamide toxicity: clinical and pharmacokinetic observations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/975731/),h,35.9,87142,DB01035,Procainamide
,3349748,tmax,"Mean ( +/- S.D.) tmax values for Procan SR and Pronestyl-SR were 2.2 +/- 0.8 hours and 3.8 +/- 1.1 hours, respectively.",Comparative bioavailability of two oral sustained-release procainamide products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349748/),h,2.2,89002,DB01035,Procainamide
,3349748,tmax,"Mean ( +/- S.D.) tmax values for Procan SR and Pronestyl-SR were 2.2 +/- 0.8 hours and 3.8 +/- 1.1 hours, respectively.",Comparative bioavailability of two oral sustained-release procainamide products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3349748/),h,3.8,89003,DB01035,Procainamide
,6091709,area under the plasma concentration-time curve,"The procainamide area under the plasma concentration-time curve was significantly (PQ0.02) increased by ranitidine (27.761.5 vs 31.561.8 mg l-1 h) with a significant reduction in renal clearance (379632 vs 309630 ml/min, PQ0.02).",Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091709/),[h·mg] / [l],27.761.5,91928,DB01035,Procainamide
,6091709,area under the plasma concentration-time curve,"The procainamide area under the plasma concentration-time curve was significantly (PQ0.02) increased by ranitidine (27.761.5 vs 31.561.8 mg l-1 h) with a significant reduction in renal clearance (379632 vs 309630 ml/min, PQ0.02).",Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091709/),[h·mg] / [l],31.561.8,91929,DB01035,Procainamide
,6091709,renal clearance,"The procainamide area under the plasma concentration-time curve was significantly (PQ0.02) increased by ranitidine (27.761.5 vs 31.561.8 mg l-1 h) with a significant reduction in renal clearance (379632 vs 309630 ml/min, PQ0.02).",Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091709/),[ml] / [min],379632,91930,DB01035,Procainamide
,6091709,renal clearance,"The procainamide area under the plasma concentration-time curve was significantly (PQ0.02) increased by ranitidine (27.761.5 vs 31.561.8 mg l-1 h) with a significant reduction in renal clearance (379632 vs 309630 ml/min, PQ0.02).",Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091709/),[ml] / [min],309630,91931,DB01035,Procainamide
,6091709,area under the plasma concentration-time curve,The N-acetylprocainamide (NAPA) area under the plasma concentration-time curve was also significantly (PQ0.02) elevated by ranitidine (8.661.2 vs 9.761.3 mg 1-1 h) due to a reduction in renal clearance from 187630 to 168628 ml/min.,Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091709/),h·mg,8.661.2,91932,DB01035,Procainamide
,6091709,area under the plasma concentration-time curve,The N-acetylprocainamide (NAPA) area under the plasma concentration-time curve was also significantly (PQ0.02) elevated by ranitidine (8.661.2 vs 9.761.3 mg 1-1 h) due to a reduction in renal clearance from 187630 to 168628 ml/min.,Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091709/),h·mg,9.761.3,91933,DB01035,Procainamide
,6091709,renal clearance,The N-acetylprocainamide (NAPA) area under the plasma concentration-time curve was also significantly (PQ0.02) elevated by ranitidine (8.661.2 vs 9.761.3 mg 1-1 h) due to a reduction in renal clearance from 187630 to 168628 ml/min.,Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091709/),[ml] / [min],187630,91934,DB01035,Procainamide
,6091709,renal clearance,The N-acetylprocainamide (NAPA) area under the plasma concentration-time curve was also significantly (PQ0.02) elevated by ranitidine (8.661.2 vs 9.761.3 mg 1-1 h) due to a reduction in renal clearance from 187630 to 168628 ml/min.,Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091709/),[ml] / [min],168628,91935,DB01035,Procainamide
,2448449,saliva to plasma concentration ratio (S/P ratio),The mean saliva to plasma concentration ratio (S/P ratio) was significantly higher in parotid (0.974 +/- 0.243) than in mandibular (0.284 +/- 0.119) saliva samples.,Mandibular and parotid salivary excretion of procainamide and N-acetylprocainamide after intravenous administration of procainamide to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2448449/),,0.974,93026,DB01035,Procainamide
,2448449,saliva to plasma concentration ratio (S/P ratio),The mean saliva to plasma concentration ratio (S/P ratio) was significantly higher in parotid (0.974 +/- 0.243) than in mandibular (0.284 +/- 0.119) saliva samples.,Mandibular and parotid salivary excretion of procainamide and N-acetylprocainamide after intravenous administration of procainamide to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2448449/),,0.284,93027,DB01035,Procainamide
,12108506,plasma trough concentrations,Intravenous procainamide doses produced pericardial fluid concentrations similar to plasma trough concentrations 0 to 12 microg/mL.,Intrapericardial therapeutics: a pharmacodynamic and pharmacokinetic comparison between pericardial and intravenous procainamide delivery. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12108506/),[μg] / [ml],0 to 12,93259,DB01035,Procainamide
,1731461,elimination half-life,"The mean elimination half-life (+/- SD) was 3.6 +/- 0.8 hours, and most of a dose (77 +/- 13%) was recovered unchanged in the urine.",Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1731461/),h,3.6,96362,DB01035,Procainamide
,2410212,metabolic clearance (CIm),"In addition to the apparent decrease in metabolic clearance (CIm) to NAPA (6.8 +/- 1.4 vs. 19.9 +/- 2.3 ml/min/kg) in the protein-deficient rats, there was a 55% decrease in the renal clearance of PA.",Disposition of procainamide and N-acetylprocainamide in protein-calorie malnutrition. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410212/),[ml] / [kg·min],6.8,100945,DB01035,Procainamide
,2410212,metabolic clearance (CIm),"In addition to the apparent decrease in metabolic clearance (CIm) to NAPA (6.8 +/- 1.4 vs. 19.9 +/- 2.3 ml/min/kg) in the protein-deficient rats, there was a 55% decrease in the renal clearance of PA.",Disposition of procainamide and N-acetylprocainamide in protein-calorie malnutrition. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410212/),[ml] / [kg·min],19.9,100946,DB01035,Procainamide
,9673780,final rate,"Treadmill speed and exercise duration were gradually increased, reaching a final rate of 24 m min-1 for an hour by the end of the 4-week or 8-week period.",The influence of moderate and chronic exercise training on the pharmacokinetics of procainamide and N-acetylprocainamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673780/),[m] / [min],24,104807,DB01035,Procainamide
,9673780,t1/2,The t1/2 of procainamide was significantly (p < 0.05) higher in the 8 week exercise group (331 min) as compared to the sedentary group (77 min).,The influence of moderate and chronic exercise training on the pharmacokinetics of procainamide and N-acetylprocainamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673780/),min,331,104808,DB01035,Procainamide
,9673780,t1/2,The t1/2 of procainamide was significantly (p < 0.05) higher in the 8 week exercise group (331 min) as compared to the sedentary group (77 min).,The influence of moderate and chronic exercise training on the pharmacokinetics of procainamide and N-acetylprocainamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673780/),min,77,104809,DB01035,Procainamide
,9673780,AUCNAPA,"In addition, there was a significant reduction in the amount of N-acetylprocainamide formed after 8 weeks of exercise (AUCNAPA = 739 ng mL-1 min-1).",The influence of moderate and chronic exercise training on the pharmacokinetics of procainamide and N-acetylprocainamide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673780/),[ng] / [min·ml],739,104810,DB01035,Procainamide
,9443381,retention times,"Following liquid-liquid extraction of plasma samples, procainamide, NAPA, and the internal standard (N-propionylprocainamide) are separated on a reversed-phase C8 column with retention times of 4.0, 6.7, and 13.2 min, respectively.",Improved high-performance liquid chromatographic assay for the determination of procainamide and its N-acetylated metabolite in plasma: application to a single-dose pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443381/),min,4.0,112326,DB01035,Procainamide
,9443381,retention times,"Following liquid-liquid extraction of plasma samples, procainamide, NAPA, and the internal standard (N-propionylprocainamide) are separated on a reversed-phase C8 column with retention times of 4.0, 6.7, and 13.2 min, respectively.",Improved high-performance liquid chromatographic assay for the determination of procainamide and its N-acetylated metabolite in plasma: application to a single-dose pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443381/),min,6.7,112327,DB01035,Procainamide
,9443381,retention times,"Following liquid-liquid extraction of plasma samples, procainamide, NAPA, and the internal standard (N-propionylprocainamide) are separated on a reversed-phase C8 column with retention times of 4.0, 6.7, and 13.2 min, respectively.",Improved high-performance liquid chromatographic assay for the determination of procainamide and its N-acetylated metabolite in plasma: application to a single-dose pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443381/),min,13.2,112328,DB01035,Procainamide
,9443381,signal-to-noise ratio,"The ultraviolet detection limit (wavelength, 280 nm) of procainamide and NAPA is 2 ng/mL (signal-to-noise ratio, 3:1), and the quantitation limit is 4 ng/mL (signal-to-noise ratio, 5:1).",Improved high-performance liquid chromatographic assay for the determination of procainamide and its N-acetylated metabolite in plasma: application to a single-dose pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443381/),,3:1,112329,DB01035,Procainamide
,9443381,signal-to-noise ratio,"The ultraviolet detection limit (wavelength, 280 nm) of procainamide and NAPA is 2 ng/mL (signal-to-noise ratio, 3:1), and the quantitation limit is 4 ng/mL (signal-to-noise ratio, 5:1).",Improved high-performance liquid chromatographic assay for the determination of procainamide and its N-acetylated metabolite in plasma: application to a single-dose pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443381/),[ng] / [ml],4,112330,DB01035,Procainamide
,9443381,signal-to-noise ratio,"The ultraviolet detection limit (wavelength, 280 nm) of procainamide and NAPA is 2 ng/mL (signal-to-noise ratio, 3:1), and the quantitation limit is 4 ng/mL (signal-to-noise ratio, 5:1).",Improved high-performance liquid chromatographic assay for the determination of procainamide and its N-acetylated metabolite in plasma: application to a single-dose pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443381/),,5:1,112331,DB01035,Procainamide
,609192,Nonrenal clearance,"Nonrenal clearance was faster (383 vs. 244 ml/min), and PA elimination half-life (t 1/2) was shorter (2.6 vs. 3.5 hr) in fast acetylators.",Kinetics of procainamide and N-acetylprocainamide in renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/609192/),[ml] / [min],383,117632,DB01035,Procainamide
,609192,Nonrenal clearance,"Nonrenal clearance was faster (383 vs. 244 ml/min), and PA elimination half-life (t 1/2) was shorter (2.6 vs. 3.5 hr) in fast acetylators.",Kinetics of procainamide and N-acetylprocainamide in renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/609192/),[ml] / [min],244,117633,DB01035,Procainamide
,609192,elimination half-life (t 1/2),"Nonrenal clearance was faster (383 vs. 244 ml/min), and PA elimination half-life (t 1/2) was shorter (2.6 vs. 3.5 hr) in fast acetylators.",Kinetics of procainamide and N-acetylprocainamide in renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/609192/),h,2.6,117634,DB01035,Procainamide
,609192,elimination half-life (t 1/2),"Nonrenal clearance was faster (383 vs. 244 ml/min), and PA elimination half-life (t 1/2) was shorter (2.6 vs. 3.5 hr) in fast acetylators.",Kinetics of procainamide and N-acetylprocainamide in renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/609192/),h,3.5,117635,DB01035,Procainamide
,609192,Nonrenal clearence,Nonrenal clearence was faster (117.5 vs. 93.5 ml/min) and PA t 1/2 shorter (10.8 vs. 17.0 hr) in fast than in slow acetylators.,Kinetics of procainamide and N-acetylprocainamide in renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/609192/),[ml] / [min],117.5,117636,DB01035,Procainamide
,609192,Nonrenal clearence,Nonrenal clearence was faster (117.5 vs. 93.5 ml/min) and PA t 1/2 shorter (10.8 vs. 17.0 hr) in fast than in slow acetylators.,Kinetics of procainamide and N-acetylprocainamide in renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/609192/),[ml] / [min],93.5,117637,DB01035,Procainamide
,609192,t 1/2,Nonrenal clearence was faster (117.5 vs. 93.5 ml/min) and PA t 1/2 shorter (10.8 vs. 17.0 hr) in fast than in slow acetylators.,Kinetics of procainamide and N-acetylprocainamide in renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/609192/),h,10.8,117638,DB01035,Procainamide
,609192,t 1/2,Nonrenal clearence was faster (117.5 vs. 93.5 ml/min) and PA t 1/2 shorter (10.8 vs. 17.0 hr) in fast than in slow acetylators.,Kinetics of procainamide and N-acetylprocainamide in renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/609192/),h,17.0,117639,DB01035,Procainamide
,609192,t 1/2,"The t 1/2 of NAPA in renal failure was 41.5 hr, in accord with predictions from studies in normal subjects, assuming no impairment in nonrenal NAPA elimination.",Kinetics of procainamide and N-acetylprocainamide in renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/609192/),h,41.5,117640,DB01035,Procainamide
,8852389,clearance,"The mean dialysis clearance was 98 mL/min, indicating effective removal of the drug by hemodialysis.",Pharmacokinetics of sematilide in renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852389/),[ml] / [min],98,119130,DB01035,Procainamide
,6166443,elimination half-life,"The plasma and tissue concentrations of NAPA declined biexponentially in parallel, with an elimination half-life of about 1.8 hr.",Tissue distribution of N-acetylprocainamide in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6166443/),h,1.8,121049,DB01035,Procainamide
,6166443,tissue/plasma ratios,"The tissue/plasma ratios for heart, kidney, and liver were 2.1, 7.9, and 2.4, respectively.",Tissue distribution of N-acetylprocainamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6166443/),,2.1,121050,DB01035,Procainamide
,6166443,tissue/plasma ratios,"The tissue/plasma ratios for heart, kidney, and liver were 2.1, 7.9, and 2.4, respectively.",Tissue distribution of N-acetylprocainamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6166443/),,7.9,121051,DB01035,Procainamide
,6166443,tissue/plasma ratios,"The tissue/plasma ratios for heart, kidney, and liver were 2.1, 7.9, and 2.4, respectively.",Tissue distribution of N-acetylprocainamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6166443/),,2.4,121052,DB01035,Procainamide
,9017761,elimination half-life,The elimination half-life of ibutilide ranges from 2-12 hours.,Ibutilide: a new class III antiarrhythmic agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9017761/),h,2-12,121444,DB01035,Procainamide
,9017761,time to conversion,The time to conversion in most trials was usually 20-30 minutes.,Ibutilide: a new class III antiarrhythmic agent. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9017761/),min,20-30,121445,DB01035,Procainamide
,1724922,renal clearance,"Acecainide renal clearance and steady-state volume of distribution were (mean +/- SD) 13.6 +/- 1.581 h-1 and 135 +/- 20.31, respectively, and were not significantly different in fast and slow acetylators.",Acecainide pharmacokinetics in normal subjects of known acetylator phenotype. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1724922/),1/[h],13.6,123224,DB01035,Procainamide
,1724922,steady-state volume of distribution,"Acecainide renal clearance and steady-state volume of distribution were (mean +/- SD) 13.6 +/- 1.581 h-1 and 135 +/- 20.31, respectively, and were not significantly different in fast and slow acetylators.",Acecainide pharmacokinetics in normal subjects of known acetylator phenotype. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1724922/),,135,123225,DB01035,Procainamide
,1724922,nonrenal clearance,"Acecainide nonrenal clearance in the six subjects was 3.0 +/- 1.01 h-1; however, nonrenal clearance in slow acetylators was 1.8 times that in fast acetylators (3.9 vs 2.21 h-1, p = 0.012) with clear separation of the subjects into two groups when the data were grouped by acetylator phenotype.",Acecainide pharmacokinetics in normal subjects of known acetylator phenotype. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1724922/),1/[h],3.0,123226,DB01035,Procainamide
,1724922,nonrenal clearance,"Acecainide nonrenal clearance in the six subjects was 3.0 +/- 1.01 h-1; however, nonrenal clearance in slow acetylators was 1.8 times that in fast acetylators (3.9 vs 2.21 h-1, p = 0.012) with clear separation of the subjects into two groups when the data were grouped by acetylator phenotype.",Acecainide pharmacokinetics in normal subjects of known acetylator phenotype. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1724922/),1/[h],3.9,123227,DB01035,Procainamide
,1724922,nonrenal clearance,"Acecainide nonrenal clearance in the six subjects was 3.0 +/- 1.01 h-1; however, nonrenal clearance in slow acetylators was 1.8 times that in fast acetylators (3.9 vs 2.21 h-1, p = 0.012) with clear separation of the subjects into two groups when the data were grouped by acetylator phenotype.",Acecainide pharmacokinetics in normal subjects of known acetylator phenotype. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1724922/),1/[h],2.21,123228,DB01035,Procainamide
,6370540,oral bioavailability,Available evidence suggests that absorption of amiodarone following oral administration is erratic and unpredictable; oral bioavailability ranges from 22 to 86%.,Clinical pharmacokinetics of amiodarone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),%,22 to 86,128509,DB01035,Procainamide
,6370540,protein binding,In vitro protein binding of amiodarone has been reported to be 96.3 +/- 0.6%.,Clinical pharmacokinetics of amiodarone. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),%,96.3,128510,DB01035,Procainamide
,6370540,plasma half-life,The plasma half-life of amiodarone after single-dose administration has been reported to be in the range of 3.2 to 79.7 hours.,Clinical pharmacokinetics of amiodarone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),h,3.2 to 79.7,128511,DB01035,Procainamide
,6370540,half-life,"However, after withdrawal of long term amiodarone treatment the half-life is as long as 100 days.",Clinical pharmacokinetics of amiodarone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),d,100,128512,DB01035,Procainamide
,6370540,Total body clearance,"Total body clearance ranges from 0.10 to 0.77 L/min after single-dose intravenous administration, and the apparent volume of distribution ranges between 0.9 and 148 L/kg.",Clinical pharmacokinetics of amiodarone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),[l] / [min],0.10 to 0.77,128513,DB01035,Procainamide
,6370540,apparent volume of distribution,"Total body clearance ranges from 0.10 to 0.77 L/min after single-dose intravenous administration, and the apparent volume of distribution ranges between 0.9 and 148 L/kg.",Clinical pharmacokinetics of amiodarone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),[l] / [kg],0.9 and 148,128514,DB01035,Procainamide
,6370540,time of onset of action,The time of onset of action of amiodarone after a single intravenous dose ranges between 1 and 30 minutes and its duration of effect between 1 and 3 hours.,Clinical pharmacokinetics of amiodarone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),min,1 and 30,128515,DB01035,Procainamide
,6370540,duration of effect,The time of onset of action of amiodarone after a single intravenous dose ranges between 1 and 30 minutes and its duration of effect between 1 and 3 hours.,Clinical pharmacokinetics of amiodarone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370540/),h,1 and 3,128516,DB01035,Procainamide
,1719744,Keo,"The pharmacodynamic parameters Keo, S, Ce(50), Emax for PA were 0.023 +/- 0.005 min-1, 3.9 +/- 1.1, 3.6 +/- 0.9 micrograms.ml-1, 37 +/- 10 ms respectively and for NAPA were 0.061 +/- 0.017 min-1, 2.2 +/- 0.4, 6.2 +/- 1.7 micrograms.ml-1, 53.6 +/- 2.5 ms.",[Combined pharmacokinetic and pharmacodynamic model analysis for procainamide and its metabolite]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719744/),1/[min],0.023,131086,DB01035,Procainamide
,1719744,S,"The pharmacodynamic parameters Keo, S, Ce(50), Emax for PA were 0.023 +/- 0.005 min-1, 3.9 +/- 1.1, 3.6 +/- 0.9 micrograms.ml-1, 37 +/- 10 ms respectively and for NAPA were 0.061 +/- 0.017 min-1, 2.2 +/- 0.4, 6.2 +/- 1.7 micrograms.ml-1, 53.6 +/- 2.5 ms.",[Combined pharmacokinetic and pharmacodynamic model analysis for procainamide and its metabolite]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719744/),1/[min],0.061,131087,DB01035,Procainamide
,1719744,S,"The pharmacodynamic parameters Keo, S, Ce(50), Emax for PA were 0.023 +/- 0.005 min-1, 3.9 +/- 1.1, 3.6 +/- 0.9 micrograms.ml-1, 37 +/- 10 ms respectively and for NAPA were 0.061 +/- 0.017 min-1, 2.2 +/- 0.4, 6.2 +/- 1.7 micrograms.ml-1, 53.6 +/- 2.5 ms.",[Combined pharmacokinetic and pharmacodynamic model analysis for procainamide and its metabolite]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719744/),[μg] / [ml],2.2,131088,DB01035,Procainamide
,1719744,Ce(50),"The pharmacodynamic parameters Keo, S, Ce(50), Emax for PA were 0.023 +/- 0.005 min-1, 3.9 +/- 1.1, 3.6 +/- 0.9 micrograms.ml-1, 37 +/- 10 ms respectively and for NAPA were 0.061 +/- 0.017 min-1, 2.2 +/- 0.4, 6.2 +/- 1.7 micrograms.ml-1, 53.6 +/- 2.5 ms.",[Combined pharmacokinetic and pharmacodynamic model analysis for procainamide and its metabolite]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719744/),1/[min],0.061,131089,DB01035,Procainamide
,1719744,Ce(50),"The pharmacodynamic parameters Keo, S, Ce(50), Emax for PA were 0.023 +/- 0.005 min-1, 3.9 +/- 1.1, 3.6 +/- 0.9 micrograms.ml-1, 37 +/- 10 ms respectively and for NAPA were 0.061 +/- 0.017 min-1, 2.2 +/- 0.4, 6.2 +/- 1.7 micrograms.ml-1, 53.6 +/- 2.5 ms.",[Combined pharmacokinetic and pharmacodynamic model analysis for procainamide and its metabolite]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719744/),[μg] / [ml],2.2,131090,DB01035,Procainamide
,1719744,Emax,"The pharmacodynamic parameters Keo, S, Ce(50), Emax for PA were 0.023 +/- 0.005 min-1, 3.9 +/- 1.1, 3.6 +/- 0.9 micrograms.ml-1, 37 +/- 10 ms respectively and for NAPA were 0.061 +/- 0.017 min-1, 2.2 +/- 0.4, 6.2 +/- 1.7 micrograms.ml-1, 53.6 +/- 2.5 ms.",[Combined pharmacokinetic and pharmacodynamic model analysis for procainamide and its metabolite]. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719744/),ms,37,131091,DB01035,Procainamide
,1719744,Emax,"The pharmacodynamic parameters Keo, S, Ce(50), Emax for PA were 0.023 +/- 0.005 min-1, 3.9 +/- 1.1, 3.6 +/- 0.9 micrograms.ml-1, 37 +/- 10 ms respectively and for NAPA were 0.061 +/- 0.017 min-1, 2.2 +/- 0.4, 6.2 +/- 1.7 micrograms.ml-1, 53.6 +/- 2.5 ms.",[Combined pharmacokinetic and pharmacodynamic model analysis for procainamide and its metabolite]. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1719744/),ms,53.6,131092,DB01035,Procainamide
,31405555,maximum serum concentration,"The average maximum serum concentration, average serum concentration, and average minimum serum concentration were 10.17, 7.13, and 3.07 μg/mL, respectively.",Pharmacokinetic evaluation of a sustained-release compounded procainamide preparation after 24-h (acute) administration in normal dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31405555/),[μg] / [ml],10.17,135051,DB01035,Procainamide
,31405555,serum concentration,"The average maximum serum concentration, average serum concentration, and average minimum serum concentration were 10.17, 7.13, and 3.07 μg/mL, respectively.",Pharmacokinetic evaluation of a sustained-release compounded procainamide preparation after 24-h (acute) administration in normal dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31405555/),[μg] / [ml],7.13,135052,DB01035,Procainamide
,31405555,minimum serum concentration,"The average maximum serum concentration, average serum concentration, and average minimum serum concentration were 10.17, 7.13, and 3.07 μg/mL, respectively.",Pharmacokinetic evaluation of a sustained-release compounded procainamide preparation after 24-h (acute) administration in normal dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31405555/),[μg] / [ml],3.07,135053,DB01035,Procainamide
,31405555,times at maximum concentration,"The average times at maximum concentration and minimum concentration were 18.67 and 12.25 h, respectively.",Pharmacokinetic evaluation of a sustained-release compounded procainamide preparation after 24-h (acute) administration in normal dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31405555/),h,18.67,135054,DB01035,Procainamide
,31405555,minimum concentration,"The average times at maximum concentration and minimum concentration were 18.67 and 12.25 h, respectively.",Pharmacokinetic evaluation of a sustained-release compounded procainamide preparation after 24-h (acute) administration in normal dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31405555/),h,12.25,135055,DB01035,Procainamide
,6193264,half-life,"At 3, 6, and 12 months of age, the half-life values of N-acetylprocainamide were 1.66, 1.82, and 2.29 hr, respectively; the apparent volumes of distribution were 4.75, 3.35, and 1.98 liter/kg, respectively.",Age-related pharmacokinetics of N-acetylprocainamide in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193264/),h,1.66,137216,DB01035,Procainamide
,6193264,half-life,"At 3, 6, and 12 months of age, the half-life values of N-acetylprocainamide were 1.66, 1.82, and 2.29 hr, respectively; the apparent volumes of distribution were 4.75, 3.35, and 1.98 liter/kg, respectively.",Age-related pharmacokinetics of N-acetylprocainamide in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193264/),h,1.82,137217,DB01035,Procainamide
,6193264,half-life,"At 3, 6, and 12 months of age, the half-life values of N-acetylprocainamide were 1.66, 1.82, and 2.29 hr, respectively; the apparent volumes of distribution were 4.75, 3.35, and 1.98 liter/kg, respectively.",Age-related pharmacokinetics of N-acetylprocainamide in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193264/),h,2.29,137218,DB01035,Procainamide
,6193264,apparent volumes of distribution,"At 3, 6, and 12 months of age, the half-life values of N-acetylprocainamide were 1.66, 1.82, and 2.29 hr, respectively; the apparent volumes of distribution were 4.75, 3.35, and 1.98 liter/kg, respectively.",Age-related pharmacokinetics of N-acetylprocainamide in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193264/),[l] / [kg],4.75,137219,DB01035,Procainamide
,6193264,apparent volumes of distribution,"At 3, 6, and 12 months of age, the half-life values of N-acetylprocainamide were 1.66, 1.82, and 2.29 hr, respectively; the apparent volumes of distribution were 4.75, 3.35, and 1.98 liter/kg, respectively.",Age-related pharmacokinetics of N-acetylprocainamide in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193264/),[l] / [kg],3.35,137220,DB01035,Procainamide
,6193264,apparent volumes of distribution,"At 3, 6, and 12 months of age, the half-life values of N-acetylprocainamide were 1.66, 1.82, and 2.29 hr, respectively; the apparent volumes of distribution were 4.75, 3.35, and 1.98 liter/kg, respectively.",Age-related pharmacokinetics of N-acetylprocainamide in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6193264/),[l] / [kg],1.98,137221,DB01035,Procainamide
,6156049,elimination half-life,"Mean (+/- SD) values for the elimination half-life, the total body clearance, and the steady-state volume of distribution were 9.53 +/- 3.22 hr, 1.98 +/- 0.40 ml/min/kg, and 1.30 +/- 0.18 1/kg.",Intravenous N-acetylprocainamide disposition kinetics in coronary artery disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6156049/),h,9.53,138301,DB01035,Procainamide
,6156049,total body clearance,"Mean (+/- SD) values for the elimination half-life, the total body clearance, and the steady-state volume of distribution were 9.53 +/- 3.22 hr, 1.98 +/- 0.40 ml/min/kg, and 1.30 +/- 0.18 1/kg.",Intravenous N-acetylprocainamide disposition kinetics in coronary artery disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6156049/),[ml] / [kg·min],1.98,138302,DB01035,Procainamide
,6156049,steady-state volume of distribution,"Mean (+/- SD) values for the elimination half-life, the total body clearance, and the steady-state volume of distribution were 9.53 +/- 3.22 hr, 1.98 +/- 0.40 ml/min/kg, and 1.30 +/- 0.18 1/kg.",Intravenous N-acetylprocainamide disposition kinetics in coronary artery disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6156049/),[1] / [kg],1.30,138303,DB01035,Procainamide
,668789,maximum serum concentration,A mean maximum serum concentration of PA of 5.78 mg/l was obtained with a loading infusion of 16.6 mg/min PA HCl.,Pharmacokinetic approach to intravenous procainamide therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/668789/),[mg] / [l],5.78,143941,DB01035,Procainamide
,668789,steady-state serum concentration,An average steady-state serum concentration of PA of 5.05 mg/l was obtained with a mean maintenance infusion of 222 mg/hour PA HCl.,Pharmacokinetic approach to intravenous procainamide therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/668789/),[mg] / [l],5.05,143942,DB01035,Procainamide
,668789,total body clearance,The total body clearance of PA in slow and fast acetylators averaged 31 and 43 l/h respectively.,Pharmacokinetic approach to intravenous procainamide therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/668789/),[l] / [h],31,143943,DB01035,Procainamide
,668789,total body clearance,The total body clearance of PA in slow and fast acetylators averaged 31 and 43 l/h respectively.,Pharmacokinetic approach to intravenous procainamide therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/668789/),[l] / [h],43,143944,DB01035,Procainamide
,8773955,Cls/Fp,"Mean PK parameters after the 50 mg/kg dose were as follows: Cls/Fprocainamide = 86.42 mL min-1 kg-1, Cls/FN-acetylprocainamide = 36.62 mL min-1 kg-1, Vdprocainamide = 10.42 L/kg, and VdN-acetylprocainamide = 5.91 L/kg.",Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773955/),[ml] / [kg·min],86.42,150905,DB01035,Procainamide
,8773955,Cls/FN,"Mean PK parameters after the 50 mg/kg dose were as follows: Cls/Fprocainamide = 86.42 mL min-1 kg-1, Cls/FN-acetylprocainamide = 36.62 mL min-1 kg-1, Vdprocainamide = 10.42 L/kg, and VdN-acetylprocainamide = 5.91 L/kg.",Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773955/),[ml] / [kg·min],36.62,150906,DB01035,Procainamide
,8773955,Vdprocainamide,"Mean PK parameters after the 50 mg/kg dose were as follows: Cls/Fprocainamide = 86.42 mL min-1 kg-1, Cls/FN-acetylprocainamide = 36.62 mL min-1 kg-1, Vdprocainamide = 10.42 L/kg, and VdN-acetylprocainamide = 5.91 L/kg.",Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773955/),[l] / [kg],10.42,150907,DB01035,Procainamide
,8773955,VdN,"Mean PK parameters after the 50 mg/kg dose were as follows: Cls/Fprocainamide = 86.42 mL min-1 kg-1, Cls/FN-acetylprocainamide = 36.62 mL min-1 kg-1, Vdprocainamide = 10.42 L/kg, and VdN-acetylprocainamide = 5.91 L/kg.",Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773955/),[l] / [kg],5.91,150908,DB01035,Procainamide
,8773955,EC50,The relationship between concentration (procainamide or N-acetylprocainamide) and effect (percent change QT interval) was best described by an Emax model for procainamide (EC50 = 445 ng/mL; Emax = 30.09%).,Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773955/),[ng] / [ml],445,150909,DB01035,Procainamide
,8773955,Emax,The relationship between concentration (procainamide or N-acetylprocainamide) and effect (percent change QT interval) was best described by an Emax model for procainamide (EC50 = 445 ng/mL; Emax = 30.09%).,Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8773955/),%,30.09,150910,DB01035,Procainamide
,2431330,peak plasma concentration,A mean peak plasma concentration of 3.2 +/- 0.6 microgram/ml was achieved about 2 h after a single 500-mg oral procainamide hydrochloride dose.,Procainamide pharmacokinetics in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2431330/),[μg] / [ml],3.2,158915,DB01035,Procainamide
,2431330,elimination half-life,The procainamide elimination half-life ranged from 6.1 to 15.3 h.,Procainamide pharmacokinetics in patients on continuous ambulatory peritoneal dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2431330/),h,6.1 to 15.3,158916,DB01035,Procainamide
,2431330,Apparent oral clearance,"Apparent oral clearance, 183.7 +/- 63.2 ml/min, was less than half that observed in healthy adults suggesting markedly reduced dosage requirements.",Procainamide pharmacokinetics in patients on continuous ambulatory peritoneal dialysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2431330/),[ml] / [min],183.7,158917,DB01035,Procainamide
,6178545,half-life,The half-life of N-acetylprocainamide in patients with normal renal function has been reported to vary between 4.3 and 15.1 hours.,Clinical pharmacokinetics of N-acetylprocainamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6178545/),h,4.3 and 15.1,160924,DB01035,Procainamide
,6178545,Total body clearance,Total body clearance (mean +/- SD) of N-acetylprocainamide in patients with normal renal function has been reported to range from 2.08 +/- 0.36 ml/min/kg to 3.28 +/- 0.52 ml/min/kg.,Clinical pharmacokinetics of N-acetylprocainamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6178545/),[ml] / [kg·min],2.08,160925,DB01035,Procainamide
,6178545,Total body clearance,Total body clearance (mean +/- SD) of N-acetylprocainamide in patients with normal renal function has been reported to range from 2.08 +/- 0.36 ml/min/kg to 3.28 +/- 0.52 ml/min/kg.,Clinical pharmacokinetics of N-acetylprocainamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6178545/),[ml] / [kg·min],3.28,160926,DB01035,Procainamide
,6178545,half-life,"The half-life of N-acetylprocainamide in functionally anephric patients may be as long as 42 hours; however, it can be effectively cleared from plasma by haemodialysis.",Clinical pharmacokinetics of N-acetylprocainamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6178545/),h,42,160927,DB01035,Procainamide
,6178545,maximum intravenous infusion rate,A maximum intravenous infusion rate of 50 mg/min has been recommended.,Clinical pharmacokinetics of N-acetylprocainamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6178545/),[mg] / [min],50,160928,DB01035,Procainamide
better,22729617,absolute recovery,"The assay precision of the method was less than 6.4%, the assay accuracy ranged between 99.6% and 101.6%, and the absolute recovery of atenolol and internal standard was better than 66.1% and 76.2%, respectively.",Determination of atenolol in human plasma by HPLC with fluorescence detection: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22729617/),%,66.1,163782,DB01035,Procainamide
,22729617,absolute recovery,"The assay precision of the method was less than 6.4%, the assay accuracy ranged between 99.6% and 101.6%, and the absolute recovery of atenolol and internal standard was better than 66.1% and 76.2%, respectively.",Determination of atenolol in human plasma by HPLC with fluorescence detection: validation and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22729617/),%,76.2,163783,DB01035,Procainamide
,6437721,apparent volume of distribution,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),l,"1300 to 11,000",168376,DB01035,Procainamide
,6437721,elimination half-life,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),d,53,168377,DB01035,Procainamide
,6437721,elimination half-life,"Although it has a short elimination half-life (1 to 3h), 2 major metabolites with antiarrhythmic effects accumulate in the plasma of patients during long term therapy.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,1 to 3,168378,DB01035,Procainamide
,6437721,elimination half-life,"Flecainide, another class Ic antiarrhythmic agent, has an elimination half-life of 14 hours which makes it suitable for twice daily dosing.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,14,168379,DB01035,Procainamide
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,9,168380,DB01035,Procainamide
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,28,168381,DB01035,Procainamide
,6437721,apparent volume of distribution,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),[l] / [kg],5.0 to 6.6,168382,DB01035,Procainamide
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,6 to 12,168383,DB01035,Procainamide
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,11 to 17,168384,DB01035,Procainamide
,6191939,renal clearance,"For its components, metabolic and renal clearance, the obese subjects showed similar metabolic clearances, but a significant increase was found in renal clearance per unit of body surface area based on both IBW (normal mean, 11.9 L/h/m2; obese, 19.0 L/h/m2) and TBW (normal mean, 11.7 L/h/m2; obese, 15.7 L/h/m2).",Procainamide disposition in obesity. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6191939/),l,11.9,170746,DB01035,Procainamide
,6191939,renal clearance,"For its components, metabolic and renal clearance, the obese subjects showed similar metabolic clearances, but a significant increase was found in renal clearance per unit of body surface area based on both IBW (normal mean, 11.9 L/h/m2; obese, 19.0 L/h/m2) and TBW (normal mean, 11.7 L/h/m2; obese, 15.7 L/h/m2).",Procainamide disposition in obesity. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6191939/),,19.0,170747,DB01035,Procainamide
,6191939,renal clearance,"For its components, metabolic and renal clearance, the obese subjects showed similar metabolic clearances, but a significant increase was found in renal clearance per unit of body surface area based on both IBW (normal mean, 11.9 L/h/m2; obese, 19.0 L/h/m2) and TBW (normal mean, 11.7 L/h/m2; obese, 15.7 L/h/m2).",Procainamide disposition in obesity. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6191939/),,11,170748,DB01035,Procainamide
,6191939,renal clearance,"For its components, metabolic and renal clearance, the obese subjects showed similar metabolic clearances, but a significant increase was found in renal clearance per unit of body surface area based on both IBW (normal mean, 11.9 L/h/m2; obese, 19.0 L/h/m2) and TBW (normal mean, 11.7 L/h/m2; obese, 15.7 L/h/m2).",Procainamide disposition in obesity. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6191939/),,15,170749,DB01035,Procainamide
,6160015,clearance ratio,The acetylprocainamide:creatinine clearance ratio averaged 1.7 +/- 0.8 and also fell with age.,Aging and renal clearance of procainamide and acetylprocainamide. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160015/),,1.7,175973,DB01035,Procainamide
,1122683,t1/2,The initial distribution after intravenous administration was rapid and the overall elimination in the beta-phase corresponded to t1/2 of 2.7 hr.,Pharmacokinetics of procainamide intravenously and orally as conventional and slow-release tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122683/),h,2.7,176207,DB01035,Procainamide
,1122683,V-d (beta),"The mean volume of the central compartment was small and only 4 percent of V-d (beta), which was 2.3 l/kg body weight.",Pharmacokinetics of procainamide intravenously and orally as conventional and slow-release tablets. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122683/),%,4,176208,DB01035,Procainamide
,1122683,V-d (beta),"The mean volume of the central compartment was small and only 4 percent of V-d (beta), which was 2.3 l/kg body weight.",Pharmacokinetics of procainamide intravenously and orally as conventional and slow-release tablets. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122683/),[l] / [kg],2.3,176209,DB01035,Procainamide
,1122683,recovery,The recovery of the metabolite N-acetylprocainamide was 12 percent after both routes of administration.,Pharmacokinetics of procainamide intravenously and orally as conventional and slow-release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122683/),%,12,176210,DB01035,Procainamide
,1122683,Renal clearance,"Renal clearance was about 500 ml/min, indicating an active secretion in the tubules.",Pharmacokinetics of procainamide intravenously and orally as conventional and slow-release tablets. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122683/),[ml] / [min],500,176211,DB01035,Procainamide
,6509861,CLR,"The mean (SE) CLR, CLA, CLO and Vd for procainamide in a 70kg patient with normal renal function were estimated to be 14.4 (2.3) L/h, 10.1 (1.7) L/h, 1.2 (1.3) L/h, and 136.0 (20.0) L, respectively.",Population pharmacokinetics of procainamide from routine clinical data. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6509861/),[l] / [h],14.4,176910,DB01035,Procainamide
,6509861,CLA,"The mean (SE) CLR, CLA, CLO and Vd for procainamide in a 70kg patient with normal renal function were estimated to be 14.4 (2.3) L/h, 10.1 (1.7) L/h, 1.2 (1.3) L/h, and 136.0 (20.0) L, respectively.",Population pharmacokinetics of procainamide from routine clinical data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6509861/),[l] / [h],10.1,176911,DB01035,Procainamide
,6509861,CLO,"The mean (SE) CLR, CLA, CLO and Vd for procainamide in a 70kg patient with normal renal function were estimated to be 14.4 (2.3) L/h, 10.1 (1.7) L/h, 1.2 (1.3) L/h, and 136.0 (20.0) L, respectively.",Population pharmacokinetics of procainamide from routine clinical data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6509861/),[l] / [h],10.1,176912,DB01035,Procainamide
,6509861,Vd,"The mean (SE) CLR, CLA, CLO and Vd for procainamide in a 70kg patient with normal renal function were estimated to be 14.4 (2.3) L/h, 10.1 (1.7) L/h, 1.2 (1.3) L/h, and 136.0 (20.0) L, respectively.",Population pharmacokinetics of procainamide from routine clinical data. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6509861/),l,136.0,176913,DB01035,Procainamide
,11258173,absolute bioavailability,Moxifloxacin has an absolute bioavailability of 90% after oral administration and a mean elimination half-life of 12 hours.,Moxifloxacin: clinical efficacy and safety. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258173/),%,90,180720,DB01035,Procainamide
,11258173,elimination half-life,Moxifloxacin has an absolute bioavailability of 90% after oral administration and a mean elimination half-life of 12 hours.,Moxifloxacin: clinical efficacy and safety. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258173/),h,12,180721,DB01035,Procainamide
,863987,recovery,The recovery of both drugs from plasma was from 95.4 to 104.8%.,Quantitative thin-layer chromatographic method for the determination of procainamide and its major metabolite in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/863987/),%,95.4 to 104.8,184642,DB01035,Procainamide
,7291727,maximum A/V ratios,"The maximum A/V ratios shortly after a rapid intravenous bolus dose were 277-, 15-, 34-, 33-, 5.4- and 3240-fold, respectively, for the above six drugs.",Arterial-venous plasma concentration differences of six drugs in the dog and rabbit after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7291727/),,27,190508,DB01035,Procainamide
,7291727,maximum A/V ratios,"The maximum A/V ratios shortly after a rapid intravenous bolus dose were 277-, 15-, 34-, 33-, 5.4- and 3240-fold, respectively, for the above six drugs.",Arterial-venous plasma concentration differences of six drugs in the dog and rabbit after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7291727/),,15,190509,DB01035,Procainamide
,832354,half-life of,"In addition, the calculated half-life of PA metabolism for slow SMZ acetylators was 9.0 to 33.8 hours (18.4 +/- 8.82) and for fast SMZ acetylators was 8.1 to 14.4 hours (10.9 +/- 2.19), P less than 0.01.",The relationship between the metabolism of procainamide and sulfamethazine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/832354/),h,9.0 to 33.8,197589,DB01035,Procainamide
,832354,half-life of,"In addition, the calculated half-life of PA metabolism for slow SMZ acetylators was 9.0 to 33.8 hours (18.4 +/- 8.82) and for fast SMZ acetylators was 8.1 to 14.4 hours (10.9 +/- 2.19), P less than 0.01.",The relationship between the metabolism of procainamide and sulfamethazine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/832354/),,18.4,197590,DB01035,Procainamide
,832354,half-life of,"In addition, the calculated half-life of PA metabolism for slow SMZ acetylators was 9.0 to 33.8 hours (18.4 +/- 8.82) and for fast SMZ acetylators was 8.1 to 14.4 hours (10.9 +/- 2.19), P less than 0.01.",The relationship between the metabolism of procainamide and sulfamethazine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/832354/),h,8.1 to 14.4,197591,DB01035,Procainamide
,832354,half-life of,"In addition, the calculated half-life of PA metabolism for slow SMZ acetylators was 9.0 to 33.8 hours (18.4 +/- 8.82) and for fast SMZ acetylators was 8.1 to 14.4 hours (10.9 +/- 2.19), P less than 0.01.",The relationship between the metabolism of procainamide and sulfamethazine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/832354/),,10.9,197592,DB01035,Procainamide
,2408690,peak serum PA concentrations,"The mean peak serum PA concentrations resulting from the low and high doses were 3.18 and 9.07 micrograms ml-1, respectively.",Concentration-dependent clearance of procainamide in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2408690/),[μg] / [ml],3.18,198102,DB01035,Procainamide
,2408690,peak serum PA concentrations,"The mean peak serum PA concentrations resulting from the low and high doses were 3.18 and 9.07 micrograms ml-1, respectively.",Concentration-dependent clearance of procainamide in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2408690/),[μg] / [ml],9.07,198103,DB01035,Procainamide
,2408690,Total PA clearance,"Total PA clearance averaged 763 ml min-1 and 577 ml min-1 while renal clearance averaged 360 ml min-1 and 318 ml min-1 after the low and high doses, respectively.",Concentration-dependent clearance of procainamide in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2408690/),[ml] / [min],763,198104,DB01035,Procainamide
,2408690,Total PA clearance,"Total PA clearance averaged 763 ml min-1 and 577 ml min-1 while renal clearance averaged 360 ml min-1 and 318 ml min-1 after the low and high doses, respectively.",Concentration-dependent clearance of procainamide in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2408690/),[ml] / [min],577,198105,DB01035,Procainamide
,2408690,renal clearance,"Total PA clearance averaged 763 ml min-1 and 577 ml min-1 while renal clearance averaged 360 ml min-1 and 318 ml min-1 after the low and high doses, respectively.",Concentration-dependent clearance of procainamide in normal subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2408690/),[ml] / [min],360,198106,DB01035,Procainamide
,2408690,renal clearance,"Total PA clearance averaged 763 ml min-1 and 577 ml min-1 while renal clearance averaged 360 ml min-1 and 318 ml min-1 after the low and high doses, respectively.",Concentration-dependent clearance of procainamide in normal subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2408690/),[ml] / [min],318,198107,DB01035,Procainamide
,2408690,Total clearance,Total clearance decreases ranged from 4.7 to 36 per cent (p less than 0.05).,Concentration-dependent clearance of procainamide in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2408690/),%,4.7 to 36,198108,DB01035,Procainamide
,8729890,trough serum quinidine concentration (SQC),A trough serum quinidine concentration (SQC) on day 7 was 6.3 micrograms/mL (normal 2-5) with normal QT and QTc intervals.,Possible pharmacokinetic interaction with quinidine: ciprofloxacin or metronidazole? ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729890/),[μg] / [ml],6.3,198923,DB01035,Procainamide
,2439252,gastric residence time,The gastric residence time of the Heidelberg capsule was prolonged by food (median 3.5 [range 1.5 to 10.0] vs. 1.0 [range 0.5 to 2.5] hours; P less than 0.02).,Food-induced gastric retention and absorption of sustained-release procainamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439252/),h,3.5,204612,DB01035,Procainamide
,2439252,gastric residence time,The gastric residence time of the Heidelberg capsule was prolonged by food (median 3.5 [range 1.5 to 10.0] vs. 1.0 [range 0.5 to 2.5] hours; P less than 0.02).,Food-induced gastric retention and absorption of sustained-release procainamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439252/),h,1.0,204613,DB01035,Procainamide
,2439252,lag time,No significant differences (median [range]; fasting vs. fed) in procainamide lag time (0.5 [0.5 to 1.0] vs. 0.5 [0.5 to 1.5] hours) or time at which peak procainamide plasma concentrations occurred (2.9 [1.0 to 4.3] vs. 2.8 [2.0 to 6.0] hours) were evident with feeding.,Food-induced gastric retention and absorption of sustained-release procainamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439252/),h,0.5,204614,DB01035,Procainamide
,2439252,lag time,No significant differences (median [range]; fasting vs. fed) in procainamide lag time (0.5 [0.5 to 1.0] vs. 0.5 [0.5 to 1.5] hours) or time at which peak procainamide plasma concentrations occurred (2.9 [1.0 to 4.3] vs. 2.8 [2.0 to 6.0] hours) were evident with feeding.,Food-induced gastric retention and absorption of sustained-release procainamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439252/),h,0.5,204615,DB01035,Procainamide
,2439252,time at which peak procainamide plasma concentrations occurred,No significant differences (median [range]; fasting vs. fed) in procainamide lag time (0.5 [0.5 to 1.0] vs. 0.5 [0.5 to 1.5] hours) or time at which peak procainamide plasma concentrations occurred (2.9 [1.0 to 4.3] vs. 2.8 [2.0 to 6.0] hours) were evident with feeding.,Food-induced gastric retention and absorption of sustained-release procainamide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439252/),h,2.9,204616,DB01035,Procainamide
,2439252,time at which peak procainamide plasma concentrations occurred,No significant differences (median [range]; fasting vs. fed) in procainamide lag time (0.5 [0.5 to 1.0] vs. 0.5 [0.5 to 1.5] hours) or time at which peak procainamide plasma concentrations occurred (2.9 [1.0 to 4.3] vs. 2.8 [2.0 to 6.0] hours) were evident with feeding.,Food-induced gastric retention and absorption of sustained-release procainamide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439252/),h,2.8,204617,DB01035,Procainamide
,17125432,clearance,"Procainamide clearance was 6.36 +/- 8.85 ml/kg/minute and correlated with creatinine clearance (r=0.78, p<0.00001) and age at day of sampling (r=0.49, p<0.00001).",Therapeutic levels of intravenous procainamide in neonates: a retrospective assessment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17125432/),[ml] / [kg·min],6.36,205078,DB01035,Procainamide
,17125432,ratio at steady state,The NAPA:procainamide ratio at steady state was 0.84 +/- 0.53; two patients were determined to be fast acetylators (ratio > 1).,Therapeutic levels of intravenous procainamide in neonates: a retrospective assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17125432/),,0.84,205079,DB01035,Procainamide
>,17125432,ratio,The NAPA:procainamide ratio at steady state was 0.84 +/- 0.53; two patients were determined to be fast acetylators (ratio > 1).,Therapeutic levels of intravenous procainamide in neonates: a retrospective assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17125432/),,1,205080,DB01035,Procainamide
,2310989,steady-state concentration,The mean steady-state concentration (23.7 +/- 8.9 mumols/L) and the adjusted mean serum procainamide concentration with Procan SR (25.3 +/- 7.9 mumols/L) were not significantly different.,Conversion from intravenous procainamide to oral sustained release tablets in cardiac patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310989/),[mumols] / [l],23.7,205298,DB01035,Procainamide
,729620,absorption half life,"97.6 +/- 27.1 (SD)% of the oral procainamide was absorbed, the absorption half life being 1.54 h.",The pharmacokinetics of slow-release procainamide. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/729620/),h,1.54,205521,DB01035,Procainamide
,729620,elimination half life,"The elimination half life following the oral formulation was 6.0 +/- 0.8 h, compared to a mean of 3.4 +/- 0.4 h following i.v. administration.",The pharmacokinetics of slow-release procainamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/729620/),h,6.0,205522,DB01035,Procainamide
,729620,elimination half life,"The elimination half life following the oral formulation was 6.0 +/- 0.8 h, compared to a mean of 3.4 +/- 0.4 h following i.v. administration.",The pharmacokinetics of slow-release procainamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/729620/),h,3.4,205523,DB01035,Procainamide
,729620,Elimination half life,"Elimination half life following i.v. administration was slightly related to acetylator status, being 2.75 +/- 0.9 h in fast acetylators, and 4.4 +/- 2.4 h in slow acetylators.",The pharmacokinetics of slow-release procainamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/729620/),h,2.75,205524,DB01035,Procainamide
,729620,Elimination half life,"Elimination half life following i.v. administration was slightly related to acetylator status, being 2.75 +/- 0.9 h in fast acetylators, and 4.4 +/- 2.4 h in slow acetylators.",The pharmacokinetics of slow-release procainamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/729620/),h,4.4,205525,DB01035,Procainamide
,6166034,absolute bioavailability,"The absolute bioavailability of NAPA from oral solution with and without feed was 87 and 90%, respectively, and from the mixed diet was 84-92%.",Bioavailability of N-acetylprocainamide from mixed diet in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6166034/),%,87,207261,DB01035,Procainamide
,6166034,absolute bioavailability,"The absolute bioavailability of NAPA from oral solution with and without feed was 87 and 90%, respectively, and from the mixed diet was 84-92%.",Bioavailability of N-acetylprocainamide from mixed diet in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6166034/),%,90,207262,DB01035,Procainamide
,6166034,absolute bioavailability,"The absolute bioavailability of NAPA from oral solution with and without feed was 87 and 90%, respectively, and from the mixed diet was 84-92%.",Bioavailability of N-acetylprocainamide from mixed diet in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6166034/),%,84-92,207263,DB01035,Procainamide
,6166034,relative bioavailability,The relative bioavailability of the drug from mixed diet ranged from 94-103%.,Bioavailability of N-acetylprocainamide from mixed diet in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6166034/),%,94-103,207264,DB01035,Procainamide
,2467982,CLR,Mean +/- S.D. base-line procainamide CLR was 539 +/- 114 ml/min for Group I vs. 410 +/- 61 ml/min for Group II (P less than .01).,Ranitidine-induced changes in the renal and hepatic clearances of procainamide are correlated. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467982/),[ml] / [min],539,208716,DB01035,Procainamide
,2467982,CLR,Mean +/- S.D. base-line procainamide CLR was 539 +/- 114 ml/min for Group I vs. 410 +/- 61 ml/min for Group II (P less than .01).,Ranitidine-induced changes in the renal and hepatic clearances of procainamide are correlated. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467982/),[ml] / [min],410,208717,DB01035,Procainamide
,3958372,half-life,"Compared with the 10 control patients, the 12 patients with acute myocardial infarction and the 15 patients with congestive heart failure had normal procainamide pharmacokinetics with respect to half-life (2.3 +/- 1.0, 2.5 +/- 0.9 and 2.6 +/- 0.8 hours, respectively), volume of distribution (1.9 +/- 0.7, 1.8 +/- 0.4 and 1.8 +/- 0.5 liters/kg, respectively), clearance (11.3 +/- 7.5, 9.3 +/- 3.6 and 9.1 +/- 3.5 ml/min per kg, respectively) and unbound drug fraction (66 +/- 9, 66 +/- 9 and 69 +/- 4%, respectively).",Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958372/),h,2.3,209466,DB01035,Procainamide
,3958372,half-life,"Compared with the 10 control patients, the 12 patients with acute myocardial infarction and the 15 patients with congestive heart failure had normal procainamide pharmacokinetics with respect to half-life (2.3 +/- 1.0, 2.5 +/- 0.9 and 2.6 +/- 0.8 hours, respectively), volume of distribution (1.9 +/- 0.7, 1.8 +/- 0.4 and 1.8 +/- 0.5 liters/kg, respectively), clearance (11.3 +/- 7.5, 9.3 +/- 3.6 and 9.1 +/- 3.5 ml/min per kg, respectively) and unbound drug fraction (66 +/- 9, 66 +/- 9 and 69 +/- 4%, respectively).",Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958372/),h,2.5,209467,DB01035,Procainamide
,3958372,half-life,"Compared with the 10 control patients, the 12 patients with acute myocardial infarction and the 15 patients with congestive heart failure had normal procainamide pharmacokinetics with respect to half-life (2.3 +/- 1.0, 2.5 +/- 0.9 and 2.6 +/- 0.8 hours, respectively), volume of distribution (1.9 +/- 0.7, 1.8 +/- 0.4 and 1.8 +/- 0.5 liters/kg, respectively), clearance (11.3 +/- 7.5, 9.3 +/- 3.6 and 9.1 +/- 3.5 ml/min per kg, respectively) and unbound drug fraction (66 +/- 9, 66 +/- 9 and 69 +/- 4%, respectively).",Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958372/),h,2.6,209468,DB01035,Procainamide
,3958372,volume of distribution,"Compared with the 10 control patients, the 12 patients with acute myocardial infarction and the 15 patients with congestive heart failure had normal procainamide pharmacokinetics with respect to half-life (2.3 +/- 1.0, 2.5 +/- 0.9 and 2.6 +/- 0.8 hours, respectively), volume of distribution (1.9 +/- 0.7, 1.8 +/- 0.4 and 1.8 +/- 0.5 liters/kg, respectively), clearance (11.3 +/- 7.5, 9.3 +/- 3.6 and 9.1 +/- 3.5 ml/min per kg, respectively) and unbound drug fraction (66 +/- 9, 66 +/- 9 and 69 +/- 4%, respectively).",Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958372/),[l] / [kg],1.9,209469,DB01035,Procainamide
,3958372,volume of distribution,"Compared with the 10 control patients, the 12 patients with acute myocardial infarction and the 15 patients with congestive heart failure had normal procainamide pharmacokinetics with respect to half-life (2.3 +/- 1.0, 2.5 +/- 0.9 and 2.6 +/- 0.8 hours, respectively), volume of distribution (1.9 +/- 0.7, 1.8 +/- 0.4 and 1.8 +/- 0.5 liters/kg, respectively), clearance (11.3 +/- 7.5, 9.3 +/- 3.6 and 9.1 +/- 3.5 ml/min per kg, respectively) and unbound drug fraction (66 +/- 9, 66 +/- 9 and 69 +/- 4%, respectively).",Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958372/),[l] / [kg],1.8,209470,DB01035,Procainamide
,3958372,volume of distribution,"Compared with the 10 control patients, the 12 patients with acute myocardial infarction and the 15 patients with congestive heart failure had normal procainamide pharmacokinetics with respect to half-life (2.3 +/- 1.0, 2.5 +/- 0.9 and 2.6 +/- 0.8 hours, respectively), volume of distribution (1.9 +/- 0.7, 1.8 +/- 0.4 and 1.8 +/- 0.5 liters/kg, respectively), clearance (11.3 +/- 7.5, 9.3 +/- 3.6 and 9.1 +/- 3.5 ml/min per kg, respectively) and unbound drug fraction (66 +/- 9, 66 +/- 9 and 69 +/- 4%, respectively).",Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958372/),[l] / [kg],1.8,209471,DB01035,Procainamide
,3958372,clearance,"Compared with the 10 control patients, the 12 patients with acute myocardial infarction and the 15 patients with congestive heart failure had normal procainamide pharmacokinetics with respect to half-life (2.3 +/- 1.0, 2.5 +/- 0.9 and 2.6 +/- 0.8 hours, respectively), volume of distribution (1.9 +/- 0.7, 1.8 +/- 0.4 and 1.8 +/- 0.5 liters/kg, respectively), clearance (11.3 +/- 7.5, 9.3 +/- 3.6 and 9.1 +/- 3.5 ml/min per kg, respectively) and unbound drug fraction (66 +/- 9, 66 +/- 9 and 69 +/- 4%, respectively).",Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958372/),[ml] / [kg·min],11.3,209472,DB01035,Procainamide
,3958372,clearance,"Compared with the 10 control patients, the 12 patients with acute myocardial infarction and the 15 patients with congestive heart failure had normal procainamide pharmacokinetics with respect to half-life (2.3 +/- 1.0, 2.5 +/- 0.9 and 2.6 +/- 0.8 hours, respectively), volume of distribution (1.9 +/- 0.7, 1.8 +/- 0.4 and 1.8 +/- 0.5 liters/kg, respectively), clearance (11.3 +/- 7.5, 9.3 +/- 3.6 and 9.1 +/- 3.5 ml/min per kg, respectively) and unbound drug fraction (66 +/- 9, 66 +/- 9 and 69 +/- 4%, respectively).",Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958372/),[ml] / [kg·min],9.3,209473,DB01035,Procainamide
,3958372,clearance,"Compared with the 10 control patients, the 12 patients with acute myocardial infarction and the 15 patients with congestive heart failure had normal procainamide pharmacokinetics with respect to half-life (2.3 +/- 1.0, 2.5 +/- 0.9 and 2.6 +/- 0.8 hours, respectively), volume of distribution (1.9 +/- 0.7, 1.8 +/- 0.4 and 1.8 +/- 0.5 liters/kg, respectively), clearance (11.3 +/- 7.5, 9.3 +/- 3.6 and 9.1 +/- 3.5 ml/min per kg, respectively) and unbound drug fraction (66 +/- 9, 66 +/- 9 and 69 +/- 4%, respectively).",Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958372/),[ml] / [kg·min],9.1,209474,DB01035,Procainamide
,3958372,unbound drug fraction,"Compared with the 10 control patients, the 12 patients with acute myocardial infarction and the 15 patients with congestive heart failure had normal procainamide pharmacokinetics with respect to half-life (2.3 +/- 1.0, 2.5 +/- 0.9 and 2.6 +/- 0.8 hours, respectively), volume of distribution (1.9 +/- 0.7, 1.8 +/- 0.4 and 1.8 +/- 0.5 liters/kg, respectively), clearance (11.3 +/- 7.5, 9.3 +/- 3.6 and 9.1 +/- 3.5 ml/min per kg, respectively) and unbound drug fraction (66 +/- 9, 66 +/- 9 and 69 +/- 4%, respectively).",Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958372/),%,66,209475,DB01035,Procainamide
,3958372,unbound drug fraction,"Compared with the 10 control patients, the 12 patients with acute myocardial infarction and the 15 patients with congestive heart failure had normal procainamide pharmacokinetics with respect to half-life (2.3 +/- 1.0, 2.5 +/- 0.9 and 2.6 +/- 0.8 hours, respectively), volume of distribution (1.9 +/- 0.7, 1.8 +/- 0.4 and 1.8 +/- 0.5 liters/kg, respectively), clearance (11.3 +/- 7.5, 9.3 +/- 3.6 and 9.1 +/- 3.5 ml/min per kg, respectively) and unbound drug fraction (66 +/- 9, 66 +/- 9 and 69 +/- 4%, respectively).",Procainamide pharmacokinetics in patients with acute myocardial infarction or congestive heart failure. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958372/),%,69,209476,DB01035,Procainamide
,2050827,renal clearance,"In particular, renal clearance was not significantly different (488 +/- 95 mL/min without probenecid vs. 478 +/- 69 mL/min in the presence of probenecid).",Effect of probenecid on the pharmacokinetics and pharmacodynamics of procainamide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050827/),[ml] / [min],488,213847,DB01035,Procainamide
,2050827,renal clearance,"In particular, renal clearance was not significantly different (488 +/- 95 mL/min without probenecid vs. 478 +/- 69 mL/min in the presence of probenecid).",Effect of probenecid on the pharmacokinetics and pharmacodynamics of procainamide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050827/),[ml] / [min],478,213848,DB01035,Procainamide
,1284402,alpha,"When PA was given alone, the pharmacokinetic parameters alpha, beta, Kmo, K1m.V1.V-1m, were 0.20 +/- 0.04, 0.016 +/- 0.003, 0.027 +/- 0.01, and 0.043 +/- 0.02 min-1, respectively.",[Effects of amiodarone on kinetics of procainamide and its major metabolite disposition in rabbit]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1284402/),1/[min],0.20,213882,DB01035,Procainamide
,1284402,V1.V-1m,"When PA was given alone, the pharmacokinetic parameters alpha, beta, Kmo, K1m.V1.V-1m, were 0.20 +/- 0.04, 0.016 +/- 0.003, 0.027 +/- 0.01, and 0.043 +/- 0.02 min-1, respectively.",[Effects of amiodarone on kinetics of procainamide and its major metabolite disposition in rabbit]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1284402/),1/[min],0.043,213883,DB01035,Procainamide
,2427689,Total apparent volume of distribution,Total apparent volume of distribution was 0.4153 +/- 0.0301 liters/kg (mean +/- S.E.M.) for the 12-mg/kg group and 0.4946 +/- 0.0691 liters/kg for the 60-mg/kg group (P greater than .05).,Cardiovascular actions and pharmacokinetics of desethyl-N-acetylprocainamide in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427689/),[l] / [kg],0.4153,213989,DB01035,Procainamide
,2427689,Total apparent volume of distribution,Total apparent volume of distribution was 0.4153 +/- 0.0301 liters/kg (mean +/- S.E.M.) for the 12-mg/kg group and 0.4946 +/- 0.0691 liters/kg for the 60-mg/kg group (P greater than .05).,Cardiovascular actions and pharmacokinetics of desethyl-N-acetylprocainamide in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427689/),[l] / [kg],0.4946,213990,DB01035,Procainamide
,2427689,Elimination clearance,Elimination clearance was 0.0061 +/- 0.0006 liters/min/kg for the 12-mg/kg group and 0.0086 +/- 0.0013 liters/min/kg for the 60-mg/kg group (P greater than .05).,Cardiovascular actions and pharmacokinetics of desethyl-N-acetylprocainamide in the dog. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427689/),[l] / [kg·min],0.0061,213991,DB01035,Procainamide
,2427689,Elimination clearance,Elimination clearance was 0.0061 +/- 0.0006 liters/min/kg for the 12-mg/kg group and 0.0086 +/- 0.0013 liters/min/kg for the 60-mg/kg group (P greater than .05).,Cardiovascular actions and pharmacokinetics of desethyl-N-acetylprocainamide in the dog. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427689/),[l] / [kg·min],0.0086,213992,DB01035,Procainamide
,2427689,elimination phase half-life (T1/2 beta),"The elimination phase half-life (T1/2 beta) was 57.0 +/- 4.1 and 53.1 +/- 3.2 min for the 12- and 60-mg/kg groups, respectively (P greater than .05).",Cardiovascular actions and pharmacokinetics of desethyl-N-acetylprocainamide in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427689/),min,57.0,213993,DB01035,Procainamide
,2427689,elimination phase half-life (T1/2 beta),"The elimination phase half-life (T1/2 beta) was 57.0 +/- 4.1 and 53.1 +/- 3.2 min for the 12- and 60-mg/kg groups, respectively (P greater than .05).",Cardiovascular actions and pharmacokinetics of desethyl-N-acetylprocainamide in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427689/),min,53.1,213994,DB01035,Procainamide
,7525982,t1/2,The PA plasma concentrations could be described by a one-compartment model with a t1/2 of 3.49 +/- 0.61 h.,The pharmacokinetics and pharmacodynamics of procainamide in horses after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7525982/),h,3.49,214939,DB01035,Procainamide
,7525982,total body clearance,The total body clearance of PA was 0.395 +/- 0.090 l/hr/kg and the volume of distribution was 1.93 +/- 0.27 l/kg.,The pharmacokinetics and pharmacodynamics of procainamide in horses after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7525982/),[l] / [h·kg],0.395,214940,DB01035,Procainamide
,7525982,volume of distribution,The total body clearance of PA was 0.395 +/- 0.090 l/hr/kg and the volume of distribution was 1.93 +/- 0.27 l/kg.,The pharmacokinetics and pharmacodynamics of procainamide in horses after intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7525982/),[l] / [kg],1.93,214941,DB01035,Procainamide
,7525982,t1/2,"As observed after PA administration, NAPA (an active metabolite) had a t1/2 longer than PA of 6.31 +/- 1.49 h.",The pharmacokinetics and pharmacodynamics of procainamide in horses after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7525982/),h,6.31,214942,DB01035,Procainamide
,7525982,Peak NAPA concentrations,Peak NAPA concentrations (1.91 +/- 0.51 micrograms/ml) occurred at 5.2 h after the PA i.v. dose.,The pharmacokinetics and pharmacodynamics of procainamide in horses after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7525982/),[μg] / [ml],1.91,214943,DB01035,Procainamide
,3581646,plasma clearance,"Compared with control, procainamide plasma clearance decreased from 0.43 +/- 0.12 L/kg-hr to 0.33 +/- 0.12 L/kg-hr (P less than 0.01), plasma elimination half-life increased from 3.77 +/- 0.64 hours to 5.21 +/- 0.42 hours (P less than 0.01), and volume of distribution was unchanged from 2.31 +/- 0.74 L/kg to 2.47 +/- 0.90 L/kg during amiodarone treatment.",Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581646/),[l] / [kg-hr],0.43,218219,DB01035,Procainamide
,3581646,plasma clearance,"Compared with control, procainamide plasma clearance decreased from 0.43 +/- 0.12 L/kg-hr to 0.33 +/- 0.12 L/kg-hr (P less than 0.01), plasma elimination half-life increased from 3.77 +/- 0.64 hours to 5.21 +/- 0.42 hours (P less than 0.01), and volume of distribution was unchanged from 2.31 +/- 0.74 L/kg to 2.47 +/- 0.90 L/kg during amiodarone treatment.",Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581646/),[l] / [kg-hr],0.33,218220,DB01035,Procainamide
,3581646,plasma elimination half-life,"Compared with control, procainamide plasma clearance decreased from 0.43 +/- 0.12 L/kg-hr to 0.33 +/- 0.12 L/kg-hr (P less than 0.01), plasma elimination half-life increased from 3.77 +/- 0.64 hours to 5.21 +/- 0.42 hours (P less than 0.01), and volume of distribution was unchanged from 2.31 +/- 0.74 L/kg to 2.47 +/- 0.90 L/kg during amiodarone treatment.",Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581646/),h,3.77,218221,DB01035,Procainamide
,3581646,plasma elimination half-life,"Compared with control, procainamide plasma clearance decreased from 0.43 +/- 0.12 L/kg-hr to 0.33 +/- 0.12 L/kg-hr (P less than 0.01), plasma elimination half-life increased from 3.77 +/- 0.64 hours to 5.21 +/- 0.42 hours (P less than 0.01), and volume of distribution was unchanged from 2.31 +/- 0.74 L/kg to 2.47 +/- 0.90 L/kg during amiodarone treatment.",Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581646/),h,5.21,218222,DB01035,Procainamide
,3581646,volume of distribution,"Compared with control, procainamide plasma clearance decreased from 0.43 +/- 0.12 L/kg-hr to 0.33 +/- 0.12 L/kg-hr (P less than 0.01), plasma elimination half-life increased from 3.77 +/- 0.64 hours to 5.21 +/- 0.42 hours (P less than 0.01), and volume of distribution was unchanged from 2.31 +/- 0.74 L/kg to 2.47 +/- 0.90 L/kg during amiodarone treatment.",Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581646/),[l] / [kg],2.31,218223,DB01035,Procainamide
,3581646,volume of distribution,"Compared with control, procainamide plasma clearance decreased from 0.43 +/- 0.12 L/kg-hr to 0.33 +/- 0.12 L/kg-hr (P less than 0.01), plasma elimination half-life increased from 3.77 +/- 0.64 hours to 5.21 +/- 0.42 hours (P less than 0.01), and volume of distribution was unchanged from 2.31 +/- 0.74 L/kg to 2.47 +/- 0.90 L/kg during amiodarone treatment.",Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581646/),[l] / [kg],2.47,218224,DB01035,Procainamide
,2416904,t1/2 beta,Our data showed significant 24 h variation of the following pharmacokinetic parameters: highest elimination half-lives at 10.00h (t1/2 beta = 0.736 +/- 0.020h) for procainamide and at 04.00h (t1/2 beta = 3.55 +/- 0.08h) for NAPA (P less than 0.001); highest apparent volume of distribution at 04.00h for procainamide (Vd = 2.35 +/- 0.17 litre) (P less than 0.05); highest ratio AUC NAPA/AUC procainamide at 04.00h (1.039 +/- 0.056) (P less than 0.001).,Circadian changes in procainamide and N-acetylprocainamide kinetics in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2416904/),h,0.736,220345,DB01035,Procainamide
,2416904,t1/2 beta,Our data showed significant 24 h variation of the following pharmacokinetic parameters: highest elimination half-lives at 10.00h (t1/2 beta = 0.736 +/- 0.020h) for procainamide and at 04.00h (t1/2 beta = 3.55 +/- 0.08h) for NAPA (P less than 0.001); highest apparent volume of distribution at 04.00h for procainamide (Vd = 2.35 +/- 0.17 litre) (P less than 0.05); highest ratio AUC NAPA/AUC procainamide at 04.00h (1.039 +/- 0.056) (P less than 0.001).,Circadian changes in procainamide and N-acetylprocainamide kinetics in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2416904/),h,3.55,220346,DB01035,Procainamide
,2416904,Vd,Our data showed significant 24 h variation of the following pharmacokinetic parameters: highest elimination half-lives at 10.00h (t1/2 beta = 0.736 +/- 0.020h) for procainamide and at 04.00h (t1/2 beta = 3.55 +/- 0.08h) for NAPA (P less than 0.001); highest apparent volume of distribution at 04.00h for procainamide (Vd = 2.35 +/- 0.17 litre) (P less than 0.05); highest ratio AUC NAPA/AUC procainamide at 04.00h (1.039 +/- 0.056) (P less than 0.001).,Circadian changes in procainamide and N-acetylprocainamide kinetics in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2416904/),l,2.35,220347,DB01035,Procainamide
,2457560,total body clearance (TBC),PA total body clearance (TBC) averaged 143 ml/min; TBC for NAPA was 29.8 ml/min.,Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2457560/),[ml] / [min],143,226719,DB01035,Procainamide
,2457560,TBC,PA total body clearance (TBC) averaged 143 ml/min; TBC for NAPA was 29.8 ml/min.,Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2457560/),[ml] / [min],29.8,226720,DB01035,Procainamide
,2457560,half-lives,"PA and NAPA half-lives were considerably prolonged averaging 26.0 and 42.8 h, respectively.",Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2457560/),h,26.0,226721,DB01035,Procainamide
,2457560,half-lives,"PA and NAPA half-lives were considerably prolonged averaging 26.0 and 42.8 h, respectively.",Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2457560/),h,42.8,226722,DB01035,Procainamide
,2457560,V beta,V beta for PA was 4.1 l/kg and for NAPA was 1.46 l/kg.,Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2457560/),[l] / [kg],4.1,226723,DB01035,Procainamide
,2457560,V beta,V beta for PA was 4.1 l/kg and for NAPA was 1.46 l/kg.,Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2457560/),[l] / [kg],1.46,226724,DB01035,Procainamide
,2457560,dialysance,"PA and NAPA dialysance varied from 0.28 to 5.55 ml/min and from 1.74 to 7.20 ml/min, respectively.",Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2457560/),[ml] / [min],0.28 to 5.55,226725,DB01035,Procainamide
,2457560,dialysance,"PA and NAPA dialysance varied from 0.28 to 5.55 ml/min and from 1.74 to 7.20 ml/min, respectively.",Pharmacokinetics of procainamide in continuous ambulatory peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2457560/),[ml] / [min],1.74 to 7.20,226726,DB01035,Procainamide
,6158263,plasma concentration,The mean plasma concentration of acecainide associated with efficacy was 14.3 micrograms/ml (range 9.4 to 19.5) and with side effects (primarily gastrointestinal) was 22.5 micrograms/ml (10.6 to 37.9).,"Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6158263/),[μg] / [ml],14.3,227232,DB01035,Procainamide
,6158263,half-life of elimination,The mean half-life of elimination after a single 500 mg dose of acecainide was 7.5 hours; this had prolonged significantly (p < 0.05) to 10.3 hours after higher dosages.,"Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6158263/),h,7.5,227233,DB01035,Procainamide
,6158263,half-life of elimination,The mean half-life of elimination after a single 500 mg dose of acecainide was 7.5 hours; this had prolonged significantly (p < 0.05) to 10.3 hours after higher dosages.,"Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6158263/),h,10.3,227234,DB01035,Procainamide
,2460613,apparent renal,"The mean apparent renal, biliary and intestinal clearance values of procainamide were 186, 1.83 and 73.9 ml/h/kg in normal rats, respectively, and were 2.02, 1.37 and 55.8 ml/h/kg in ARF rats respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],186,227677,DB01035,Procainamide
,2460613,apparent renal,"The mean apparent renal, biliary and intestinal clearance values of procainamide were 186, 1.83 and 73.9 ml/h/kg in normal rats, respectively, and were 2.02, 1.37 and 55.8 ml/h/kg in ARF rats respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],1.83,227678,DB01035,Procainamide
,2460613,apparent renal,"The mean apparent renal, biliary and intestinal clearance values of procainamide were 186, 1.83 and 73.9 ml/h/kg in normal rats, respectively, and were 2.02, 1.37 and 55.8 ml/h/kg in ARF rats respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],2.02,227679,DB01035,Procainamide
,2460613,biliary,"The mean apparent renal, biliary and intestinal clearance values of procainamide were 186, 1.83 and 73.9 ml/h/kg in normal rats, respectively, and were 2.02, 1.37 and 55.8 ml/h/kg in ARF rats respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],1.83,227680,DB01035,Procainamide
,2460613,biliary,"The mean apparent renal, biliary and intestinal clearance values of procainamide were 186, 1.83 and 73.9 ml/h/kg in normal rats, respectively, and were 2.02, 1.37 and 55.8 ml/h/kg in ARF rats respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],73.9,227681,DB01035,Procainamide
,2460613,biliary,"The mean apparent renal, biliary and intestinal clearance values of procainamide were 186, 1.83 and 73.9 ml/h/kg in normal rats, respectively, and were 2.02, 1.37 and 55.8 ml/h/kg in ARF rats respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],2.02,227682,DB01035,Procainamide
,2460613,biliary,"The mean apparent renal, biliary and intestinal clearance values of procainamide were 186, 1.83 and 73.9 ml/h/kg in normal rats, respectively, and were 2.02, 1.37 and 55.8 ml/h/kg in ARF rats respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],1.37,227683,DB01035,Procainamide
,2460613,biliary,"The mean apparent renal, biliary and intestinal clearance values of procainamide were 186, 1.83 and 73.9 ml/h/kg in normal rats, respectively, and were 2.02, 1.37 and 55.8 ml/h/kg in ARF rats respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],55.8,227684,DB01035,Procainamide
,2460613,intestinal clearance,"The mean apparent renal, biliary and intestinal clearance values of procainamide were 186, 1.83 and 73.9 ml/h/kg in normal rats, respectively, and were 2.02, 1.37 and 55.8 ml/h/kg in ARF rats respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],73.9,227685,DB01035,Procainamide
,2460613,intestinal clearance,"The mean apparent renal, biliary and intestinal clearance values of procainamide were 186, 1.83 and 73.9 ml/h/kg in normal rats, respectively, and were 2.02, 1.37 and 55.8 ml/h/kg in ARF rats respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],2.02,227686,DB01035,Procainamide
,2460613,intestinal clearance,"The mean apparent renal, biliary and intestinal clearance values of procainamide were 186, 1.83 and 73.9 ml/h/kg in normal rats, respectively, and were 2.02, 1.37 and 55.8 ml/h/kg in ARF rats respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],1.37,227687,DB01035,Procainamide
,2460613,intestinal clearance,"The mean apparent renal, biliary and intestinal clearance values of procainamide were 186, 1.83 and 73.9 ml/h/kg in normal rats, respectively, and were 2.02, 1.37 and 55.8 ml/h/kg in ARF rats respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],55.8,227688,DB01035,Procainamide
,2460613,renal,"Furthermore, the mean renal, biliary and intestinal clearance values of NAPA were 35.2, 19.4 and 21.1 ml/h/kg in normal rats, respectively, and were 1.12, 21.0 and 26.0 ml/h/kg in ARF rats, respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],35.2,227689,DB01035,Procainamide
,2460613,renal,"Furthermore, the mean renal, biliary and intestinal clearance values of NAPA were 35.2, 19.4 and 21.1 ml/h/kg in normal rats, respectively, and were 1.12, 21.0 and 26.0 ml/h/kg in ARF rats, respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],1.12,227690,DB01035,Procainamide
,2460613,biliary,"Furthermore, the mean renal, biliary and intestinal clearance values of NAPA were 35.2, 19.4 and 21.1 ml/h/kg in normal rats, respectively, and were 1.12, 21.0 and 26.0 ml/h/kg in ARF rats, respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],19.4,227691,DB01035,Procainamide
,2460613,biliary,"Furthermore, the mean renal, biliary and intestinal clearance values of NAPA were 35.2, 19.4 and 21.1 ml/h/kg in normal rats, respectively, and were 1.12, 21.0 and 26.0 ml/h/kg in ARF rats, respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],21.1,227692,DB01035,Procainamide
,2460613,biliary,"Furthermore, the mean renal, biliary and intestinal clearance values of NAPA were 35.2, 19.4 and 21.1 ml/h/kg in normal rats, respectively, and were 1.12, 21.0 and 26.0 ml/h/kg in ARF rats, respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],1.12,227693,DB01035,Procainamide
,2460613,biliary,"Furthermore, the mean renal, biliary and intestinal clearance values of NAPA were 35.2, 19.4 and 21.1 ml/h/kg in normal rats, respectively, and were 1.12, 21.0 and 26.0 ml/h/kg in ARF rats, respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],21.0,227694,DB01035,Procainamide
,2460613,intestinal clearance,"Furthermore, the mean renal, biliary and intestinal clearance values of NAPA were 35.2, 19.4 and 21.1 ml/h/kg in normal rats, respectively, and were 1.12, 21.0 and 26.0 ml/h/kg in ARF rats, respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],21.1,227695,DB01035,Procainamide
,2460613,intestinal clearance,"Furthermore, the mean renal, biliary and intestinal clearance values of NAPA were 35.2, 19.4 and 21.1 ml/h/kg in normal rats, respectively, and were 1.12, 21.0 and 26.0 ml/h/kg in ARF rats, respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],21.0,227696,DB01035,Procainamide
,2460613,intestinal clearance,"Furthermore, the mean renal, biliary and intestinal clearance values of NAPA were 35.2, 19.4 and 21.1 ml/h/kg in normal rats, respectively, and were 1.12, 21.0 and 26.0 ml/h/kg in ARF rats, respectively.",Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2460613/),[ml] / [h·kg],26.0,227697,DB01035,Procainamide
,2189614,bioavailability,Pharmacokinetic studies have shown that oral absorption is rapid with bioavailability of 80-90%.,Mexiletine: pharmacology and therapeutic use. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189614/),%,80-90,228858,DB01035,Procainamide
,2189614,elimination half-life,Mexiletine is predominantly metabolized by the liver with elimination half-life of 9 to 12 hours.,Mexiletine: pharmacology and therapeutic use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189614/),h,9 to 12,228859,DB01035,Procainamide
,6161089,half-life,"In fast acetylators (sulphadimidine phenotyping), half-life was shorter (2.4 +/- 0.7 hr) and 24 hr urine NAPA excretion was larger (22.5 +/- 5.8% of dose) than in slow acetylators (3.6 +/- 1.0 hr and 8.8 +/- 5.4% respectively).",Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6161089/),h,2.4,232219,DB01035,Procainamide
,6161089,excretion,"In fast acetylators (sulphadimidine phenotyping), half-life was shorter (2.4 +/- 0.7 hr) and 24 hr urine NAPA excretion was larger (22.5 +/- 5.8% of dose) than in slow acetylators (3.6 +/- 1.0 hr and 8.8 +/- 5.4% respectively).",Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6161089/),%,22.5,232220,DB01035,Procainamide
,6161089,excretion,"In fast acetylators (sulphadimidine phenotyping), half-life was shorter (2.4 +/- 0.7 hr) and 24 hr urine NAPA excretion was larger (22.5 +/- 5.8% of dose) than in slow acetylators (3.6 +/- 1.0 hr and 8.8 +/- 5.4% respectively).",Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6161089/),h,3.6,232221,DB01035,Procainamide
,6161089,excretion,"In fast acetylators (sulphadimidine phenotyping), half-life was shorter (2.4 +/- 0.7 hr) and 24 hr urine NAPA excretion was larger (22.5 +/- 5.8% of dose) than in slow acetylators (3.6 +/- 1.0 hr and 8.8 +/- 5.4% respectively).",Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6161089/),%,8.8,232222,DB01035,Procainamide
,6161089,t 1/2,"NAPA was characterized by different pharmacokinetic parameters (t 1/2 7.0 +/- 1.0 hr, 24 hr urine elimination - 58.5% of dose).",Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6161089/),h,7.0,232223,DB01035,Procainamide
,6161089,urine elimination,"NAPA was characterized by different pharmacokinetic parameters (t 1/2 7.0 +/- 1.0 hr, 24 hr urine elimination - 58.5% of dose).",Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6161089/),h,24,232224,DB01035,Procainamide
,619132,systemic availability,The systemic availability of PA was estimated to be 78%.,The quantitative disposition of procainamide and N-acetylprocainamide in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/619132/),%,78,235220,DB01035,Procainamide
,619132,half-life (T 1/2),The half-life (T 1/2) of PA elimination was 55 minutes and that of NAPA was 51 minutes.,The quantitative disposition of procainamide and N-acetylprocainamide in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/619132/),min,55,235221,DB01035,Procainamide
,619132,half-life (T 1/2),The half-life (T 1/2) of PA elimination was 55 minutes and that of NAPA was 51 minutes.,The quantitative disposition of procainamide and N-acetylprocainamide in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/619132/),min,51,235222,DB01035,Procainamide
,619132,clearance,PA clearance was 64 ml/kg/min and NAPA clearance 22.4 ml/kg/min.,The quantitative disposition of procainamide and N-acetylprocainamide in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/619132/),[ml] / [kg·min],64,235223,DB01035,Procainamide
,619132,clearance,PA clearance was 64 ml/kg/min and NAPA clearance 22.4 ml/kg/min.,The quantitative disposition of procainamide and N-acetylprocainamide in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/619132/),[ml] / [kg·min],22.4,235224,DB01035,Procainamide
,619132,apparent distribution volume,The apparent distribution volume for PA was 4.92 liters/kg and for NAPA 1.64 liters/kg.,The quantitative disposition of procainamide and N-acetylprocainamide in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/619132/),[l] / [kg],4.92,235225,DB01035,Procainamide
,619132,apparent distribution volume,The apparent distribution volume for PA was 4.92 liters/kg and for NAPA 1.64 liters/kg.,The quantitative disposition of procainamide and N-acetylprocainamide in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/619132/),[l] / [kg],1.64,235226,DB01035,Procainamide
,17616997,concentrations,"The procainamide concentrations 1 hour after administration was highest in group C (mean, 11.59 microg/mL) followed by group A (9.92 microg/mL), whereas group B (7.44 microg/mL) and control group D (7.36 microg/mL) showed comparable values.",Drug-herb interaction: effect of St John's wort on bioavailability and metabolism of procainamide in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17616997/),[μg] / [ml],11,235652,DB01035,Procainamide
,17616997,bioavailability,"In a separate experiment when mice were fed purified hypericin, the active component of St John's wort, a significant increase in bioavailability (53%) of procainamide was observed compared with the control group.",Drug-herb interaction: effect of St John's wort on bioavailability and metabolism of procainamide in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17616997/),%,53,235653,DB01035,Procainamide
,886461,Kel,"Two-compartment open modeling of the plasma levels from the intravenous infusion experiments yielded mean Kel, k12, and k21 values of 0.0162, 0.0542, and 0.0233 min-1, respectively.",Absorption kinetics of procainamide in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/886461/),1/[min],0.0162,248260,DB01035,Procainamide
,886461,k12,"Two-compartment open modeling of the plasma levels from the intravenous infusion experiments yielded mean Kel, k12, and k21 values of 0.0162, 0.0542, and 0.0233 min-1, respectively.",Absorption kinetics of procainamide in humans. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/886461/),1/[min],0.0542,248261,DB01035,Procainamide
,886461,k21,"Two-compartment open modeling of the plasma levels from the intravenous infusion experiments yielded mean Kel, k12, and k21 values of 0.0162, 0.0542, and 0.0233 min-1, respectively.",Absorption kinetics of procainamide in humans. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/886461/),1/[min],0.0233,248262,DB01035,Procainamide
,886461,bioavailability,The bioavailability of the oral preparations (versus intravenous) averaged 83% for the capsule and 79% for the sustained-release tablet.,Absorption kinetics of procainamide in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/886461/),%,83,248263,DB01035,Procainamide
,886461,bioavailability,The bioavailability of the oral preparations (versus intravenous) averaged 83% for the capsule and 79% for the sustained-release tablet.,Absorption kinetics of procainamide in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/886461/),%,79,248264,DB01035,Procainamide
,886461,ka's,"Calculations using a previously reported method suggested that absorption was a first-order process with mean ka's of 0.0336 and 0.0039 min-1 for the capsule and sustained-release tablet, respectively.",Absorption kinetics of procainamide in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/886461/),1/[min],0.0336,248265,DB01035,Procainamide
,886461,ka's,"Calculations using a previously reported method suggested that absorption was a first-order process with mean ka's of 0.0336 and 0.0039 min-1 for the capsule and sustained-release tablet, respectively.",Absorption kinetics of procainamide in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/886461/),1/[min],0.0039,248266,DB01035,Procainamide
,91468,elimination t 1/2,"Distribution and nonrenal elimination of this drug were found to be the same as in individuals with normal renal function but renal clearance was reduced, resulting in a mean elimination t 1/2 of 41.9 hr (6.2 hr in normal subjects).",N-Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/91468/),h,41.9,250260,DB01035,Procainamide
,91468,elimination t 1/2,"Distribution and nonrenal elimination of this drug were found to be the same as in individuals with normal renal function but renal clearance was reduced, resulting in a mean elimination t 1/2 of 41.9 hr (6.2 hr in normal subjects).",N-Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/91468/),h,6.2,250261,DB01035,Procainamide
,3373418,total body clearances,"Lignocaine and procainamide mean total body clearances were 2.9 L/min (SD 1.1) and 1.3 L/min (SD 0.2), respectively.",The uptake and elution of lignocaine and procainamide in the hindquarters of the sheep described using mass balance principles. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3373418/),[l] / [min],2.9,250746,DB01035,Procainamide
,3373418,total body clearances,"Lignocaine and procainamide mean total body clearances were 2.9 L/min (SD 1.1) and 1.3 L/min (SD 0.2), respectively.",The uptake and elution of lignocaine and procainamide in the hindquarters of the sheep described using mass balance principles. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3373418/),[l] / [min],1.3,250747,DB01035,Procainamide
,1261157,peak serum levels,The rapid acetylators had higher peak serum levels of NAPA (1.80 mug/ml) than the slow acetylators (0.40 mug/ml).,N-Acetylprocainamide levels in patients with end-stage renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261157/),[μg] / [ml],1.80,251762,DB01035,Procainamide
,1261157,peak serum levels,The rapid acetylators had higher peak serum levels of NAPA (1.80 mug/ml) than the slow acetylators (0.40 mug/ml).,N-Acetylprocainamide levels in patients with end-stage renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261157/),[μg] / [ml],0.40,251763,DB01035,Procainamide
,1261157,half-life (T1/2),"The half-life (T1/2) of PA was shorter, 2.5 hr, in the rapid acetylators than in the slow, 4.1 hr.",N-Acetylprocainamide levels in patients with end-stage renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261157/),h,2.5,251764,DB01035,Procainamide
,1261157,half-life (T1/2),"The half-life (T1/2) of PA was shorter, 2.5 hr, in the rapid acetylators than in the slow, 4.1 hr.",N-Acetylprocainamide levels in patients with end-stage renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261157/),h,4.1,251765,DB01035,Procainamide
,1261157,Clearance,Clearance of NAPA during clinical hemodialysis was 48 +/- 10 cc/min compared to 75 +/- 12 ml/min for PA.,N-Acetylprocainamide levels in patients with end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261157/),[cc] / [min],48,251766,DB01035,Procainamide
,1261157,Clearance,Clearance of NAPA during clinical hemodialysis was 48 +/- 10 cc/min compared to 75 +/- 12 ml/min for PA.,N-Acetylprocainamide levels in patients with end-stage renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261157/),[ml] / [min],75,251767,DB01035,Procainamide
,3385724,half-life,"After iv administration to rats, procainamide was extensively metabolized to N-acetylprocainamide and displayed a half-life of 0.4 h.","Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3385724/),h,0.4,253042,DB01035,Procainamide
,3385724,half-life,"In contrast, dimethylprocainamide was not metabolized by N-acetylation, had a half-life of 1.4 h, and provided greater peak plasma concentrations.","Electrophysiologic and antiarrhythmic activities of 4-amino-N-[2-(diethylamino)ethyl]-3,5-dimethylbenzamide, a sterically hindered procainamide analogue. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3385724/),h,1.4,253043,DB01035,Procainamide
,1707209,Emax,"The values of Emax, Keo, S, EC50 were found to be 120 +/- 13.2 ms, 0.0182 +/- 0.007 min-1, 2.26 +/- 0.93, 6.31 +/- 0.71 microgram/ml respectively following intravenous infusion; the corresponding values following iv administration were 53.6 +/- 2.5 ms, 0.061 +/- 0.017 min-1, 2.19 +/- 0.39, 6.21 +/- 1.74 micrograms/ml respectively.",[Combined pharmacokinetic--pharmacodynamic model analysis of N-acetyl procainamids following intravenous infusion in rabbits]. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1707209/),ms,120,258120,DB01035,Procainamide
,1707209,Keo,"The values of Emax, Keo, S, EC50 were found to be 120 +/- 13.2 ms, 0.0182 +/- 0.007 min-1, 2.26 +/- 0.93, 6.31 +/- 0.71 microgram/ml respectively following intravenous infusion; the corresponding values following iv administration were 53.6 +/- 2.5 ms, 0.061 +/- 0.017 min-1, 2.19 +/- 0.39, 6.21 +/- 1.74 micrograms/ml respectively.",[Combined pharmacokinetic--pharmacodynamic model analysis of N-acetyl procainamids following intravenous infusion in rabbits]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1707209/),1/[min],0.0182,258121,DB01035,Procainamide
,1707209,Keo,"The values of Emax, Keo, S, EC50 were found to be 120 +/- 13.2 ms, 0.0182 +/- 0.007 min-1, 2.26 +/- 0.93, 6.31 +/- 0.71 microgram/ml respectively following intravenous infusion; the corresponding values following iv administration were 53.6 +/- 2.5 ms, 0.061 +/- 0.017 min-1, 2.19 +/- 0.39, 6.21 +/- 1.74 micrograms/ml respectively.",[Combined pharmacokinetic--pharmacodynamic model analysis of N-acetyl procainamids following intravenous infusion in rabbits]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1707209/),ms,53.6,258122,DB01035,Procainamide
,1707209,Keo,"The values of Emax, Keo, S, EC50 were found to be 120 +/- 13.2 ms, 0.0182 +/- 0.007 min-1, 2.26 +/- 0.93, 6.31 +/- 0.71 microgram/ml respectively following intravenous infusion; the corresponding values following iv administration were 53.6 +/- 2.5 ms, 0.061 +/- 0.017 min-1, 2.19 +/- 0.39, 6.21 +/- 1.74 micrograms/ml respectively.",[Combined pharmacokinetic--pharmacodynamic model analysis of N-acetyl procainamids following intravenous infusion in rabbits]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1707209/),1/[min],0.061,258123,DB01035,Procainamide
,1707209,S,"The values of Emax, Keo, S, EC50 were found to be 120 +/- 13.2 ms, 0.0182 +/- 0.007 min-1, 2.26 +/- 0.93, 6.31 +/- 0.71 microgram/ml respectively following intravenous infusion; the corresponding values following iv administration were 53.6 +/- 2.5 ms, 0.061 +/- 0.017 min-1, 2.19 +/- 0.39, 6.21 +/- 1.74 micrograms/ml respectively.",[Combined pharmacokinetic--pharmacodynamic model analysis of N-acetyl procainamids following intravenous infusion in rabbits]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1707209/),1/[min],0.0182,258124,DB01035,Procainamide
,1707209,S,"The values of Emax, Keo, S, EC50 were found to be 120 +/- 13.2 ms, 0.0182 +/- 0.007 min-1, 2.26 +/- 0.93, 6.31 +/- 0.71 microgram/ml respectively following intravenous infusion; the corresponding values following iv administration were 53.6 +/- 2.5 ms, 0.061 +/- 0.017 min-1, 2.19 +/- 0.39, 6.21 +/- 1.74 micrograms/ml respectively.",[Combined pharmacokinetic--pharmacodynamic model analysis of N-acetyl procainamids following intravenous infusion in rabbits]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1707209/),ms,53.6,258125,DB01035,Procainamide
,1707209,S,"The values of Emax, Keo, S, EC50 were found to be 120 +/- 13.2 ms, 0.0182 +/- 0.007 min-1, 2.26 +/- 0.93, 6.31 +/- 0.71 microgram/ml respectively following intravenous infusion; the corresponding values following iv administration were 53.6 +/- 2.5 ms, 0.061 +/- 0.017 min-1, 2.19 +/- 0.39, 6.21 +/- 1.74 micrograms/ml respectively.",[Combined pharmacokinetic--pharmacodynamic model analysis of N-acetyl procainamids following intravenous infusion in rabbits]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1707209/),1/[min],0.061,258126,DB01035,Procainamide
,1707209,EC50,"The values of Emax, Keo, S, EC50 were found to be 120 +/- 13.2 ms, 0.0182 +/- 0.007 min-1, 2.26 +/- 0.93, 6.31 +/- 0.71 microgram/ml respectively following intravenous infusion; the corresponding values following iv administration were 53.6 +/- 2.5 ms, 0.061 +/- 0.017 min-1, 2.19 +/- 0.39, 6.21 +/- 1.74 micrograms/ml respectively.",[Combined pharmacokinetic--pharmacodynamic model analysis of N-acetyl procainamids following intravenous infusion in rabbits]. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1707209/),[μg] / [ml],2.26,258127,DB01035,Procainamide
,1707209,EC50,"The values of Emax, Keo, S, EC50 were found to be 120 +/- 13.2 ms, 0.0182 +/- 0.007 min-1, 2.26 +/- 0.93, 6.31 +/- 0.71 microgram/ml respectively following intravenous infusion; the corresponding values following iv administration were 53.6 +/- 2.5 ms, 0.061 +/- 0.017 min-1, 2.19 +/- 0.39, 6.21 +/- 1.74 micrograms/ml respectively.",[Combined pharmacokinetic--pharmacodynamic model analysis of N-acetyl procainamids following intravenous infusion in rabbits]. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1707209/),[μg] / [ml],6.31,258128,DB01035,Procainamide
,1707209,EC50,"The values of Emax, Keo, S, EC50 were found to be 120 +/- 13.2 ms, 0.0182 +/- 0.007 min-1, 2.26 +/- 0.93, 6.31 +/- 0.71 microgram/ml respectively following intravenous infusion; the corresponding values following iv administration were 53.6 +/- 2.5 ms, 0.061 +/- 0.017 min-1, 2.19 +/- 0.39, 6.21 +/- 1.74 micrograms/ml respectively.",[Combined pharmacokinetic--pharmacodynamic model analysis of N-acetyl procainamids following intravenous infusion in rabbits]. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1707209/),[μg] / [ml],2.19,258129,DB01035,Procainamide
,1707209,EC50,"The values of Emax, Keo, S, EC50 were found to be 120 +/- 13.2 ms, 0.0182 +/- 0.007 min-1, 2.26 +/- 0.93, 6.31 +/- 0.71 microgram/ml respectively following intravenous infusion; the corresponding values following iv administration were 53.6 +/- 2.5 ms, 0.061 +/- 0.017 min-1, 2.19 +/- 0.39, 6.21 +/- 1.74 micrograms/ml respectively.",[Combined pharmacokinetic--pharmacodynamic model analysis of N-acetyl procainamids following intravenous infusion in rabbits]. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1707209/),[μg] / [ml],6.21,258130,DB01035,Procainamide
,694230,Cpss,"Overall the mean steady state plasma concentration of PA (Cpss) expressed as a fraction of dose did not depend on dose or on acetylator status, but the HS group had significantly higher Cpss per gram dose (6.3 mug/ml) than LS (2.7 mug/ml) or the HF (2.3 mug/ml) groups.",Capacity-limited elimination of procainamide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/694230/),[μg] / [ml],6.3,262776,DB01035,Procainamide
,694230,Cpss,"Overall the mean steady state plasma concentration of PA (Cpss) expressed as a fraction of dose did not depend on dose or on acetylator status, but the HS group had significantly higher Cpss per gram dose (6.3 mug/ml) than LS (2.7 mug/ml) or the HF (2.3 mug/ml) groups.",Capacity-limited elimination of procainamide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/694230/),[μg] / [ml],2.7,262777,DB01035,Procainamide
,694230,Cpss,"Overall the mean steady state plasma concentration of PA (Cpss) expressed as a fraction of dose did not depend on dose or on acetylator status, but the HS group had significantly higher Cpss per gram dose (6.3 mug/ml) than LS (2.7 mug/ml) or the HF (2.3 mug/ml) groups.",Capacity-limited elimination of procainamide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/694230/),[μg] / [ml],2.3,262778,DB01035,Procainamide
,694230,C1A,C1A was not dose-dependent in the HF or LF groups (mean 177.9 ml/min and 168.4 ml/min) but was dose-dependent in the HS group (mean 74.6 ml/min) which differed significantly from the LS group (mean 113.4 ml/min).,Capacity-limited elimination of procainamide in man. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/694230/),[ml] / [min],177.9,262779,DB01035,Procainamide
,694230,C1A,C1A was not dose-dependent in the HF or LF groups (mean 177.9 ml/min and 168.4 ml/min) but was dose-dependent in the HS group (mean 74.6 ml/min) which differed significantly from the LS group (mean 113.4 ml/min).,Capacity-limited elimination of procainamide in man. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/694230/),[ml] / [min],168.4,262780,DB01035,Procainamide
,694230,C1A,C1A was not dose-dependent in the HF or LF groups (mean 177.9 ml/min and 168.4 ml/min) but was dose-dependent in the HS group (mean 74.6 ml/min) which differed significantly from the LS group (mean 113.4 ml/min).,Capacity-limited elimination of procainamide in man. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/694230/),[ml] / [min],74.6,262781,DB01035,Procainamide
,694230,C1A,C1A was not dose-dependent in the HF or LF groups (mean 177.9 ml/min and 168.4 ml/min) but was dose-dependent in the HS group (mean 74.6 ml/min) which differed significantly from the LS group (mean 113.4 ml/min).,Capacity-limited elimination of procainamide in man. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/694230/),[ml] / [min],113.4,262782,DB01035,Procainamide
,954350,terminal half-life,"The following average pharmacokinetic parameters for plasma were found: terminal half-life, 2.9 hr; total clearance, 828 ml/min; renal clearance, 334 ml/min; and steady-state volume of distribution, 180 L.",Relationship between the pharmacokinetics and pharmacodynamics of procainamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/954350/),h,2.9,265830,DB01035,Procainamide
,954350,total clearance,"The following average pharmacokinetic parameters for plasma were found: terminal half-life, 2.9 hr; total clearance, 828 ml/min; renal clearance, 334 ml/min; and steady-state volume of distribution, 180 L.",Relationship between the pharmacokinetics and pharmacodynamics of procainamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954350/),[ml] / [min],828,265831,DB01035,Procainamide
,954350,renal clearance,"The following average pharmacokinetic parameters for plasma were found: terminal half-life, 2.9 hr; total clearance, 828 ml/min; renal clearance, 334 ml/min; and steady-state volume of distribution, 180 L.",Relationship between the pharmacokinetics and pharmacodynamics of procainamide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954350/),[ml] / [min],334,265832,DB01035,Procainamide
,954350,steady-state volume of distribution,"The following average pharmacokinetic parameters for plasma were found: terminal half-life, 2.9 hr; total clearance, 828 ml/min; renal clearance, 334 ml/min; and steady-state volume of distribution, 180 L.",Relationship between the pharmacokinetics and pharmacodynamics of procainamide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954350/),l,180,265833,DB01035,Procainamide
,954350,distribution pseudoequilbrium half-time (t1/2 alpha),Average distribution pseudoequilbrium half-time (t1/2 alpha) was 5.2 min from an initial volume of distribution of 36.6 L.,Relationship between the pharmacokinetics and pharmacodynamics of procainamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954350/),min,5.2,265834,DB01035,Procainamide
,954350,volume of distribution,Average distribution pseudoequilbrium half-time (t1/2 alpha) was 5.2 min from an initial volume of distribution of 36.6 L.,Relationship between the pharmacokinetics and pharmacodynamics of procainamide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954350/),l,36.6,265835,DB01035,Procainamide
,458558,total body clearances (ClT),"The total body clearances (ClT) of PA in slow and fast acetylators were 22.6 and 34.8 liters/hr, respectively.",Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/458558/),[l] / [h],22.6,267921,DB01035,Procainamide
,458558,total body clearances (ClT),"The total body clearances (ClT) of PA in slow and fast acetylators were 22.6 and 34.8 liters/hr, respectively.",Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/458558/),[l] / [h],34.8,267922,DB01035,Procainamide
,458558,fraction of,The fraction of PA cleared by the formation of NAPA in the corresponding acetylator group was 0.2 and 0.4.,Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/458558/),,0.2,267923,DB01035,Procainamide
,458558,fraction of,The fraction of PA cleared by the formation of NAPA in the corresponding acetylator group was 0.2 and 0.4.,Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/458558/),,0.4,267924,DB01035,Procainamide
,458558,ClT's,"Renal impairment affected the pharmacokinetics of PA more profoundly as the ClT's of PA in patients with and without renal impairment were 17.9 and 31.2 liters/hr, respectively.",Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/458558/),[l] / [h],17.9,267925,DB01035,Procainamide
,458558,ClT's,"Renal impairment affected the pharmacokinetics of PA more profoundly as the ClT's of PA in patients with and without renal impairment were 17.9 and 31.2 liters/hr, respectively.",Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/458558/),[l] / [h],31.2,267926,DB01035,Procainamide
